Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial

Casey R. Ager[1,2,3,4,†], Aleksandar Obradovic[5,†], Patrick McCann[6], Matthew Chaimowitz[2], Alexander L. E. Wang[5], Neha Shaikh[7], Parin Shah[7], Samuel Pan[7], Caroline J. Laplaca[8], Renu K. Virk[9], Jessica C. Hill[3], Collin Jugler[3], Grace DeFranco[3], Nilika Bhattacharya[3], Howard I. Scher[10], Guarionex Joel DeCastro[8], Christopher B. Anderson[8], James M. McKiernan[8], Catherine S. Spina[6], Mark N. Stein[1], Karie Runcie[1], Charles G. Drake[1,8,15], Andrea Califano[5,7,11,12,13,14], Matthew C. Dallos[1,10]

[1] Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY
[2] Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
[3] Department of Immunology, Mayo Clinic Arizona, Scottsdale, AZ
[4] Department of Urology, Mayo Clinic Arizona, Scottsdale, AZ
[5] Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY
[6] Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY
[7] Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
[8] Department of Urology, Columbia University Irving Medical Center, New York, NY
[9] Department of Pathology, Columbia University Irving Medical Center, New York, NY
[10] Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
[11] Department of Biochemistry & Molecular Biophysics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA 10032
[12] Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA 10032
[13] Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA 10032
[14] Chan Zuckerberg Biohub New York, New York, NY, USA
[15] Current Address: JnJ Innovative Medicine, Springhouse, PA
[†] These authors contributed equally

Running Title: Fc-Modified anti-CTLA-4 Depletes Tregs in Prostate Cancer
Keywords: Regulatory T Cell, CTLA-4, Ipilimumab, Prostate Cancer, Neoadjuvant, CyTOF, single cell RNA sequencing
Funding: This research was supported by National Institutes of Health (NIH) grants 1P50CA58236-15 and P30CA006973, the Prostate Cancer Foundation Challenge Grant, TJ Martell Foundation funds, and CUMC institutional funds to C.G.D, the NCI's Center for Cancer Systems Therapeutics (CaST) award U54CA274506, the NCI Outstanding Investigator award R35 CA197745, and the NIH Shared Instrumentation Grants S10 OD012351, S10 OD021764 and S10OD032433, to A.C., by a Prostate Cancer Foundation Young Investigator Award to M.D., by NIH grants UL1TR001873 and TL1TR001875, and institutional funds from Mayo Clinic to C.R.A., by NIH grant F30CA260765-01 to A.O., and by NIH/NIDDK grant T35DK093430 in support of A.L.E.W.
Correspondence: Dr. Matthew Dallos (dallosm@mskcc.org)
Conflicts of Interest: C.G.D is a co-inventor on patents licensed from Johns Hopkins University to BMS and Janssen. He is currently a paid employee of JnJ Innovative Medicine. A.C. is founder, equity holder, consultant, and director of DarwinHealth Inc., which has licensed IP related to these algorithms from Columbia University. Columbia University is an equity holder in DarwinHealth Inc.

Abstract

Men with high-risk localized prostate cancer exhibit high rates of post-surgical recurrence. In these patients, androgen deprivation therapy (ADT) is immunomodulatory, however increased infiltration of regulatory T cells (Tregs) may limit the antitumor immune effects of ADT. We designed a neoadjuvant clinical trial to test whether BMS-986218 – a next-generation non-fucosylated anti-CTLA-4 antibody engineered for enhanced antibody-dependent cellular cytotoxicity or phagocytosis (ADCC/P) – depletes intratumoral Tregs and augments the response to ADT. In this single-center, two-arm, open-label study, 24 men with high-risk localized prostate cancer were randomized to receive a single dose of ADT with or without two pre-operative doses of BMS-986218 (anti-CTLA4-NF) prior to radical prostatectomy. Treatment was well tolerated and feasible in the neoadjuvant setting. A secondary clinical outcome was the rate of disease recurrence, which was lower than predicted in both arms. Mechanistically, anti-CTLA4-NF reduced ADT-induced Treg accumulation through engagement of CD16a/*FCGR3A* on tumor macrophages, and depth of Treg depletion was quantitatively associated with clinical outcome. Increased intratumoral dendritic cell (DC) frequencies also associated with lack of recurrence, and pre-clinical data suggest ADCC/P-competent anti-CTLA-4 antibodies elicit activation and expansion of tumor DCs. Patients receiving anti-CTLA4-NF also exhibited phenotypic signatures of enhanced antitumor T cell priming. In total, this study provides the first-in-human evidence of Treg depletion by glycoengineered antibodies targeting CTLA-4 in humans and their potential in combination with ADT in prostate cancer patients with high-risk of recurrence.

Introduction

To date, immune checkpoint blockade immunotherapy (ICB) has proven largely ineffective for patients with prostate cancer (PCa)[1]. Agents targeting the PD-1/PD-L1 pathway alone or in combination with androgen receptor inhibitors (KEYNOTE-164[2], KEYNOTE-991[3], IMbassador250[4]), chemotherapy (KEYNOTE-921[5]), or PARP inhibition (KEYLYNK-010[6]) have failed in phase III trials. Similarly, CTLA-4 blockade in a chemo-naïve population (Ipi-095[7]) or post-docetaxel in combination with bone-targeted radiation (Ipi-043[8]) did not meet pre-specified endpoints. However, long-term follow-up on the Ipi-043 trial indicates a potential survival advantage of ipilimumab versus placebo[8]. Furthermore, a phase II study of combination ipilimumab and nivolumab in metastatic patients pre- or post-chemotherapy (CheckMate-650[9]) showed a survival signal as compared to historical anti-PD-(L)1 monotherapy controls[9]. These findings suggest that CTLA-4 blockade may possess clinical activity in PCa that warrants further investigation, particularly if concerns regarding dose-dependent toxicity can be addressed

One hypothesis explaining the relatively low efficacy of ICB in PCa is that baseline T cell infiltration is insufficient for ICB to elicit robust T cell-mediated antitumor immunity[1]. Interestingly, our prior findings showed that standard of care androgen deprivation therapy (ADT) initially increases CD8 T cell infiltration into primary PCa in both murine models and patients[10,11]. However, a counter-regulatory influx of immunosuppressive $CD4^{+}FoxP3^{+}$ regulatory T cells (Tregs) inhibits the inflammatory effects of ADT, implicating adaptive Treg resistance as a critical inhibitory mechanism[10,11]. As such, depletion of tumor-infiltrating Tregs (TI-Tregs) by anti-CTLA-4 antibodies with enhanced

antibody dependent cellular cytotoxicity or phagocytosis (ADCC/P) extends depth and duration of response to androgen deprivation (ADT) in murine models, whereas non-depleting anti-CTLA-4 antibodies and PD-1 blockade in the same setting is ineffective[10]. These Fc-enhanced agents have also been hypothesized to have an improved therapeutic index[12]. Therefore, we reasoned that inhibiting TI-Treg number and/or function in combination with ADT may effectively potentiate ICB efficacy in PCa.

Methods for depleting TI-Tregs have been studied thoroughly in pre-clinical models but have as yet not been successfully validated in the clinic. Antibodies targeting cell surface proteins enriched on TI-Tregs such as CTLA-4, CD25, CCR4, TIGIT, and CCR8 have either failed to show Treg depletion activity and/or efficacy in clinical trials or remain under investigation[13-16]. We thus sought to further investigate anti-CTLA-4 in this context, given its potential clinical activity in PCa[8] and the fact that the first-generation anti-CTLA-4 antibodies ipilimumab and tremelimumab were not optimized for Treg depletion. Tremelimumab is a human IgG2 antibody with relatively low affinity for the FcγRs such as CD16a (*FCGR3A*) that mediate ADCC/P, while Ipilimumab is a human IgG1 isotype that can elicit ADCC/P. However, existing clinical data suggest ipilimumab is a weak depleter, with evidence of Treg depletion restricted to patients with a high-affinity germline polymorphic variant of *FCGR3A* (V158F)[16,17]. To overcome this limitation, antibodies targeting CTLA-4 bearing non-fucosylated Fc regions have been recently developed to enhance binding to CD16a/*FCGRIIIA*, resulting in enhanced ADCP/ADCC[18]. However, it remains unclear whether non-fucosylated anti-CTLA-4 antibodies may be more effective in depleting TI-Tregs in patients. Furthermore,

whether these next-generation Fc-enhanced antibodies may overcome adaptive Treg resistance following ADT is also unknown.

To address this challenge, we designed a randomized neoadjuvant clinical trial to evaluate the safety, feasibility, clinical efficacy, and immunological activity of non-fucosylated ipilimumab (BMS-986218; hereafter anti-CTLA4-NF) with ADT versus ADT alone prior to surgery in men with high-risk localized prostate cancer (NeoRED-P; NCT04301414). This window-of-opportunity trial enabled careful interrogation of the immunological mechanisms of response to anti-CTLA4-NF through orthogonal immunoprofiling by single cell RNA sequencing (scRNAseq), mass cytometry (CyTOF), and spatial proteomics (multiplex immunofluorescence). We also leveraged the novel RNA-seq-based pipeline PISCES to perform robust protein activity level assessment of tumor microenvironment subpopulations and of their drug-mediated depletion, thus bridging the transcriptomic and proteomic datasets. Pre-clinical validation studies in the syngeneic MycCaP PCa model closely mirrored observed immunological correlates of clinical response. Our findings demonstrate the tolerability and promising clinical activity of ADT plus anti-CTLA4-NF in the neoadjuvant setting and provide a first-in-human examination of whether Fc-engineered non-fucosylated anti-CTLA4 antibody variants mediate TI-Treg depletion, while identifying additional putative mechanisms by which anti-CTLA4-NF antibodies may augment antitumor immune responses in PCa.

Results

Treatment Safety, Feasibility and Efficacy as Neoadjuvant Therapy in Prostate Cancer

Between February 26, 2020, and November 15, 2022, 24 patients were enrolled at Columbia University Irving Medical Center. The first four patients received ADT with degarelix acetate + anti-CTLA4-NF as a safety lead-in, after which 20 patients were randomized 1:1 to ADT-only or ADT + anti-CTLA4-NF arms (Figure 1A). One patient in the ADT + anti-CTLA4-NF arm did not receive surgery due to operating room closure during SARS-CoV2 pandemic, and one patient in each arm was lost to follow-up (Figure 1B). For correlative studies, samples from a cohort of twelve stage- and grade-matched treatment-naïve patients were collected as untreated controls. Baseline characteristics of trial patients are summarized in Table 1. The arms were well balanced with respect to age, race and ethnicity, pre-treatment serum PSA or testosterone, and rate of nodal involvement or surgical margin involvement. Patients in the ADT + anti-CTLA4-NF arm trended towards modestly higher grade group 5 disease and higher predicted recurrence risk as measured by a validated risk nomogram (see Methods) than the ADT alone arm. Tumor exome and mutational profiling of all patient-derived samples showed 12 patients with AR-V7 splice variants (38%), eight patients exhibiting TMRPSS2:ERG fusion events (25%), four patients bearing mutated *TP53* (13%), three patients with copy number loss or mutations in *PTEN* (9%), and two patients each with alterations *in APC* and *CTNNB1* (6%; Extended Data Figure 1A). Of note, a single non-recurring patient in the ADT + anti-CTLA4-NF arm was found to exhibit high tumor mutational burden (TMB-H; 26 mutations/Mb), associated with a germline mutation in *MSH2*.

Treatment related adverse advents (TRAE) of any grade were observed in 80% of ADT-only patients and 71% of ADT + anti-CTLA4-NF patients, the most common events were injection site reactions in both arms (Table 2). Three Grade 1-2 gastrointestinal events were observed in patients receiving anti-CTLA4-NF. Severe treatment-related adverse events (Grade ≥ 3) were rare; a single patient in the ADT + anti-CTLA4-NF arm exhibited a Grade 3 asymptomatic serum lipase elevation that resolved without additional therapy and did not result in treatment discontinuation. No unexpected surgical complications were observed, supporting a tolerable safety profile for the addition of anti-CTLA4-NF to ADT in this patient population.

In the ADT-only arm, 80% of patients had an undetectable PSA at 12 months, with a median recurrence-free survival of 1.61 years (IQR: 1.50–1.99 years) (Table 3). In the ADT + anti-CTLA4-NF arm, 75% had an undetectable PSA at 12 months, with a median recurrence-free survival of 1.82 years (IQR: 0.89–2.07 years) (Table 3). The overall recurrence rate in patients treated with ADT + anti-CTLA4-NF was 29% (4 of 12 evaluable patients) and 20% (2 of 10 patients) in the ADT alone arm (Table 3). This study was not powered to compare efficacy between treatment arms. However, after predicting 2-year recurrence rates on a per-patient basis using a validated clinical risk nomogram (Memorial Sloan Kettering Cancer Center Post-Radical Prostatectomy Prediction; see Methods), we found both arms exceeded predicted 2-year recurrence-free survival rates (Figure 1C-D). Patients in the ADT-only arm had a PSA50 response rate prior to surgery of 33%, while patients in the ADT + anti-CTLA4-NF arm had a PSA50 response rate of 54% (p=0.4; Table 3; Figure 1E-F). All patients recovered testosterone to baseline levels within 6 months of prostatectomy (Extended Data Figure

2). Overall, these data suggest adding anti-CTLA4-NF to ADT is well-tolerated and feasible in the neoadjuvant setting for patients with high-risk localized PCa.

Anti-CTLA4-NF suppresses ADT-induced Treg expansion

To elucidate the effects of ADT + anti-CTLA4-NF versus ADT alone versus no treatment on prostate tumor-infiltrating immune populations, we performed transcriptomic and proteomic-based immune profiling via paired scRNA sequencing (via 10X Genomics droplet-based platform), mass cytometry (CyTOF), and immunofluorescence (IF; Figure 2A). Of the 36 patients assessed, 26 had scRNAseq data of sufficient quality, 25 had CyTOF data of sufficient quality, and 29 had IF data of sufficient quality to be included in further analyses (see Extended Data Figure 3A and methods for QC criteria and Figure 2B for a representative schematic). We first tested our secondary endpoint hypothesis that anti-CTLA4-NF reduces TI-Treg density in ADT-treated PCa tumors by quantifying the number of $CD4^{+}FoxP3^{+}$ Tregs per mm^2 in whole-tissue FFPE slides by IF (see representative staining images in Figure 2C). For this analysis, we censored one patient with MSI^{hi} status given the known association between MSI^{hi} status, high TMB, and increased overall tumor T cell infiltration relative to MSI^{WT} patients[19]. In line with our previous findings, we found ADT significantly increases Treg densities in the PCa tumor parenchyma (p=0.001; Figure 2D). Concurrent treatment with ADT and anti-CTLA4-NF resulted in a strong trend towards reduction in Treg density (p=0.06), indicating anti-CTLA4-NF may have measurable Treg depletion activity.

To validate these results, we interrogated the immune TME of this cohort by scRNAseq and CyTOF performed on independent, freshly processed prostatectomy specimens.

For scRNAseq data analysis we utilized the novel PISCES pipeline incorporating unbiased Louvain-based clustering and metaVIPER (virtual inference of protein activity by enriched regulon analysis[20]) to quantitatively infer activity of approximately 6,500 regulatory proteins per cell[21]. Based on CITE-seq analysis and experimental validation, this approach has been shown to outperform traditional gene expression-based methods, wherein RNA dropout limits detection of key lineage- and function-determining transcripts and reduces cluster resolution (see Methods for more detail and prior studies[21-23] for pipeline validation). Integrating cells from all patients, we stratified immune metaclusters corresponding to immune lineages including T/NK cells, B cells, macrophage/DCs, monocytes, neutrophils, and plasma cells by PISCES and cross-validated cluster identity at the gene expression level by parallel SingleR[24] and supervised annotation (Figure 2E-F). Additionally, we identified stromal cell clusters including fibroblasts, endothelial cells, megakaryocyte-erythroid progenitors (MEPs), club/glandular cells, and four molecularly distinct epithelial tumor clusters. Tumor cell clusters were validated by aberrant copy number analysis, using inferCNV[25,26] (Extended Data Figure 3B). In parallel, we performed semi-supervised FlowSOM[27] clustering followed by supervised UMAP embedding on all live CD45+ events from the CyTOF dataset (Extended Data Figure 4A; see methods for workflow details). We clearly resolved multiple immune populations using established lineage-defining protein markers, including multiple T cell subsets, NK cells, monocytes, macrophage/DCs, and neutrophils (Figure 2G-H). Further validating the PISCES-based stratification, comparative analysis of immune lineages defined by both platforms revealed significant immune subpopulation fraction correlations between scRNAseq and CyTOF for all

immune lineages on a per-patient basis. NK cells were a notable exception and were not significantly correlated across platforms (Extended Data Fig 4B). Though correlated, neutrophils were comparably underrepresented in the scRNAseq data relative to CyTOF, as is common in droplet-based scRNAseq methodologies (Extended Data Figure 3C-D). These data overall confirm faithful capture and annotation of relevant cell types by both scRNAseq and CyTOF.

To test the hypothesis that anti-CTLA4-NF mediates intratumoral Treg depletion *in vivo*, we first subclustered the scRNAseq T/NK cell metacluster to clearly resolve a Treg cluster as validated by enrichment of established Treg transcriptional signature scores, inferred activity of Treg lineage marker proteins by VIPER, and SingleR annotation (Figure 2I-K). Mirroring the IF data, patients receiving ADT + anti-CTLA4-NF exhibited a strong trending decrease in Treg frequency as compared to ADT alone (p=0.06; Figure 2L). In the CyTOF dataset, Tregs were clearly identified at the protein level in a FlowSOM-derived cluster expressing the canonical $CD4^{+}CD25^{+}CD127^{-}FoxP3^{+}$ phenotype (Figure 2M) and additional markers indicative of tumor-infiltrating Tregs including Helios, CCR8, TIGIT, CD39, and CCR4 (Figure 2N). Consistent with the PISCES analyses and IF results, we observed a non-significant but consistent trend towards a reduction in Treg frequency in the ADT + anti-CTLA4-NF arm compared to the ADT alone arm (Figure 2O; p=0.07). Though the traditional significance threshold was not reached by individual modalities, these data are highly consistent across three independent immune profiling platforms in a small, prospectively treated patient cohort, and thus suggest non-fucosylated anti-CTLA-4 antibody BMS-986218 may reduce intratumoral Treg frequencies in prostate cancer.

Increased depletion of phenotypically activated Tregs associates with clinical response

As our data suggests Treg depletion via anti-CTLA4-NF is limited in depth, we sought to further validate and investigate the biological activity of anti-CTLA4-NF by interrogating the molecular phenotype of residual Tregs in post-treatment tumors. We utilized the CyTOF data for this analysis, as we captured an insufficient number of Tregs by scRNAseq to permit rigorous subclustering of the TI-Treg compartment. Semi-supervised FlowSOM subclustering and PaCMAP embedding of TI-Tregs in the CyTOF dataset identified nine phenotypically distinct Treg subpopulations. These were primarily resolved by differential expression of CD45RO, Ki67, granzyme B, CD39, CCR8, HLA-DR, and/or 4-1BB (Figure 3A-C). This analysis revealed a potential phenotypic shift in residual Tregs for patients treated with anti-CTLA4-NF, including a decrease in Tregs in cluster Tr.5 defined by low CD39 expression, and increase in Tregs in cluster Tr.9, as defined by high expression of 4-1BB and other activation markers (Figure 3D-E). To validate these observations, we measured the fold change in geometric MFI (gMFI) of all phenotypic markers in our CyTOF panel between Tregs in patients treated with ADT versus patients treated with anti-CTLA4-NF (Figure 3F). We found Tregs remaining in tumors after anti-CTLA4-NF exposure expressed the activation markers 4-1BB, CD39, CCR8, CTLA-4, and CD25, suggesting that tumor-infiltrating Tregs remaining after anti-CTLA4-NF are enriched for an activated phenotype (Figure 3F).

Given this observation, we next examined whether the depth of TI-Treg depletion observed in treated patients associated with clinical response. For this, we stratified patients that received ADT + anti-CTLA4-NF by recurrence (n=4) versus non-recurrence

(n=7) according to clinically annotated PSA recurrence within 2 years following surgery. We limited this analysis to the scRNAseq dataset, as we did not capture CyTOF data for all patients that recurred. We found that TI-Treg frequencies at time of surgery were significantly higher in patients that went on to recur as compared to those that did not recur (p=0.03; Figure 3G). In contrast, no other lymphocyte subset was significantly associated with clinical outcome (Extended Data Figure 4E). In addition, we stratified patients that received ADT + anti-CTLA4-NF by TI-Treg frequency and found that patients with high TI-Treg frequencies exhibited significantly shorter time-to-recurrence as compared to patients with low TI-Treg frequencies (p=0.0008; Figure 3H). There were insufficient recurrence events in the ADT alone arm to perform a statistical analysis of time-to-recurrence in ADT-treated patients stratified by TI-Treg frequency, though no trend was observed (Extended Data Figure 4F). In agreement with this data, it is unlikely TI-Treg frequency in absence of anti-CTLA4-NF would associate with recurrence in this setting as prior studies show no association between Treg frequency and recurrence risk in localized PCa[28]. These correlative findings thus suggest that depth of TI-Treg depletion is associated with response to ADT + anti-CTLA4-NF in patients with high-risk localized prostate cancer.

Efficiency of myeloid-mediated Treg depletion associates with duration of response to therapy

Given the putative association between anti-CTLA4-NF-mediated TI-Treg depletion and clinical response, we next sought to investigate potential mechanisms for TI-Treg depletion. In pre-clinical models, antibody-mediated Treg depletion by anti-CTLA4 canonically requires interactions between the anti-CTLA4 Fc region and activating

FcγRs such as CD16a (*FCGR3A*) on tumor-associated macrophages (TAMs)[29,30]. To determine whether macrophage FcγR expression was associated with Treg depletion efficiency in response to ADT + anti-CTLA4-NF, we first annotated macrophage populations in the scRNAseq dataset by both supervised manual annotation and through systematic testing of established prostate cancer macrophage gene expression signatures[31] (Figure 4A-C). We identified 3 putative macrophage subsets: a recently described prostate-specific MT^+ macrophage subset[31] and two subsets of TAMs defined by TREM2 and CD206 (*MRC1)*, respectively. Of these, $TREM2^+$ and $CD206^+$ TAMs exhibited highest predicted protein activity for multiple FcγRs (Figure 4D), and $TREM2^+$ TAMs showed the highest activity of the activating FcγR CD16a/*FCGR3A* (Figure 4E). To test the hypothesis that anti-CTLA4-NF depletes Tregs through CD16a/*FCGR3A* on TAMs, we examined whether CD16a/*FCGR3A* protein activity was correlated with intratumoral TI-Treg frequencies on a per-patient basis. We found predicted CD16a/*FCGR3A* protein activity across all myeloid subsets to be significantly correlated with reduced Treg frequencies in ADT + anti-CTLA4-NF patients (p=0.033; Figure 4F). In contrast, we found no significant correlation between myeloid CD16a/*FCGR3A* protein activity and TI-Treg frequencies in patients who received ADT alone (p=0.223; Figure 4F), supporting the hypothesis that CD16a/*FCGR3A* mediates TI-Treg depletion in the context of treatment with anti-CTLA4-NF. We also found similar correlations between TI-Treg frequencies and CD16a/*FCGR3A* activity within the $TREM2^+$ TAMs specifically (Figure 4G). These findings support the notion that TI-Treg depletion by anti-CTLA4-NF is at least partially mediated through canonical tumor macrophage FcγR interactions in the human PCa tumor microenvironment.

Intratumoral dendritic cell frequencies associate with response to ADT + anti-CTLA4-NF

Overall, myeloid frequencies were not significantly altered by treatment (Figure 4H). After stratification of ADT + anti-CTLA4-NF patients by recurrence status, however, we observed intratumoral dendritic cell (DC) frequencies at time of surgery trended towards higher abundance in patients that did not recur (p=0.06; Figure 4I). We thus stratified patients by DC frequency at time of surgery and found those with fewer tumor-infiltrating DCs exhibited a significantly shorter time to recurrence (p=0.029; Figure 4J). To further investigate this novel association between DC frequencies and anti-CTLA4-NF response, we returned to the MycCaP pre-clinical model of castration-sensitive prostate cancer where we previously assessed mechanistic effects of ADCC-competent versus ADCC-incompetent anti-CTLA4 antibodies in combination with ADT[10]. We implanted 8–10-week-old male FVB mice with syngeneic Myc-CaP prostate tumors and performed chemical castration with degarelix acetate (ADT) when tumors averaged ~200mm^3 in volume (Figure 4K). Mice received a single dose of ADT alone or in combination with three doses of anti-CTLA-4 (clone 9D9; 5 mg/kg) administered IP at three-day intervals. To confirm Treg depletion was mediated through FcγR-dependent ADCC, mice received either Fc-competent antibody (mIgG2a; anti-CTLA4 [D]) or the equivalent clone and isotype bearing a mutation that nullifies FcγR interactions[32] (mIgG2a-LALAPG; anti-CTLA4 [ND]). These data were consistent with our prior findings that anti-CTLA4 (D), but not anti-CTLA4 (ND), augments response to ADT in the Myc-CaP model (Figure 4L-M). Following treatment, tumors and draining lymph nodes were harvested and profiled by 45-parameter spectral flow cytometry, and data was analyzed by semi-supervised FlowSOM clustering and supervised UMAP or unsupervised PaCMAP

embedding for visualization (Figure 4N; Extended Data Fig 5A-B). Consistent with patient data, ADT + anti-CTLA4 (D) significantly reduced Treg frequencies compared to ADT and ADT + anti-CTLA4 (ND) groups, indicating robust antibody-dependent Treg depletion (p=0.0031; Figure 4O, top). We further found that animals treated with ADT + anti-CTLA4 (D) exhibited significantly greater frequencies of tumor-infiltrating CD11c^{+} MHC-II^{hi} DCs compared to those receiving ADT or ADT + anti-CTLA4 (ND) (p=0.0009; Figure 4O). Systematic subclustering of the tumor DC compartment revealed a striking phenotypic shift in DCs in response to anti-CTLA4 (D) (Figure 4P, Extended Data Fig 5C-D). While DC phenotypes in mice treated with ADT or ADT + anti-CTLA4 (ND) were enriched for canonical cDC1 and cDC2 markers such as CD103 or CD11b, respectively, nearly all DCs in mice treated with anti-CTLA-4 (D) expressed PD-L2, a marker of the DC3 subset and/or mRegDC (mature DC enriched in immunoregulatory molecules) program. The mRegDC phenotype is induced upon tumor antigen uptake, and mRegDCs are thought to possess a unique role in shaping antitumor immune responses[33]. The increase in PD-L2^{+} DCs was unique to mice receiving anti-CTLA4 (D) (Figure 4Q, Extended Data Fig 5E). Taken together, these data indicate ADCC/P competent antibodies targeting CTLA-4 modulate tumor-infiltrating DCs, and that an increased DC frequency following treatment with anti-CTLA4-NF is associated with positive clinical outcome.

ADT + anti-CTLA-4-NF enhances antitumor T cell priming

Given the observed effects of anti-CTLA4-NF therapy on tumor Treg frequencies and myeloid phenotypes, we next sought to interrogate the effect of ADT + anti-CTLA4-NF on CD8 T cell responses in the tumor. For enhanced resolution of CD8 phenotypes in

the scRNAseq data, we first refined the previously compiled CD8-1 and CD8-2 clusters (Figure 2K), removing a contaminating cell population presenting low *Cd8a* expression, moderate *Cd4* expression, and an otherwise naïve gene signature (Extended Data Fig 6A-B). Subcluster analysis of the curated CD8 T cells resulted in an optimal three cluster solution (Figure 5A). Utilizing established pan-cancer CD8 T cell gene signatures from Zheng *et al.*[34] and prostate CD8 T cell signatures from Tuong *et al.*[31] we annotated these clusters as central memory (IL7R^{+} memory signature enrichment, prostate CD8 memory T cell signature enrichment, expression of CCR7), effector memory (enrichment of GZMK^{+} early TEM signature), and effector/resident memory CD8 T cells (enrichment of prostate CD8 effector T cell signature, expression of CD103, GzmB, TOX2; Figure 6B). These subsets were not significantly altered by ADT or ADT + anti-CTLA4-NF. To further interrogate tumor-infiltrating CD8 T cell phenotypes by CyTOF, we used semi-supervised FlowSOM clustering to define eight CD8 T cell subclusters (Figure 6D). While these clusters did not map precisely onto the three cluster solution in the scRNAseq data, we did observe clusters that most closely matched the effector memory (Tc.4; CD45RA^{-}CD45RO^{+}CD27^{+}HLA-DR^{+}PD-1^{mid}) phenotype and cells that matched the effector/resident memory (Tc.6; CD45RO^{-}HLA-DR^{+}CTLA-4^{+}TIGIT^{+}GzmB^{+}) phenotype that mirrored non-significant trends in the scRNAseq data after anti-CTLA4-NF (Extended Data Fig 6C-D). Notably, we also observed a cluster with clear enrichment in a subset of patients receiving ADT + anti-CTLA4-NF defined by 4-1BB and CD39 (Figure 5E-G), markers that are associated with recently primed and tumor-specific T cells[35,36]. We found the dual 4-1BB^{+}CD39^{+} phenotype to also define a distinct subset of CD4^{+}FoxP3^{-} conventional CD4 T cells (Tconv) that were uniquely present in a

subset of patients receiving ADT + anti-CTLA4-NF (Figure 5H-K, Extended Data 6E-F). These data suggest anti-CTLA4-NF may enhance priming of tumor-specific T cell populations, either in concert with or independent of Treg depletion. To test whether this effect requires FcγR interactions, we returned to our murine model where we profiled effects of anti-CTLA4 (D) versus anti-CTLA4 (ND) in combination with ADT. We observed a distinct cluster of 4-1BB^{+}CD39^{+} CD8 T cells in Myc-CaP tumors that were uniquely induced by ADT + anti-CTLA4 (D) and were absent in ADT-only and ADT + anti-CTLA4 (ND) groups (Figure 5L-O, Extended Data Fig 6G-I), indicating FcγR engagement is required for induction of the 4-1BB^{+}CD39^{+} CD8 T cell phenotype under anti-CTLA4 therapy. Supporting our hypothesis that these cells represent a recently primed population, we found a significant increase in CD8 and CD4 Tconv cells bearing phenotypic markers of recent priming (CD44^{+}Ki67^{+}) in tumor draining LNs (tdLNs) in mice receiving anti-CTLA4 (D) relative to anti-CTLA4 (ND) or ADT alone (Figure 5P-R, Extended Data Fig 6J). This was not associated with Treg depletion in the tdLNs, but rather an increase in Treg frequency in the tdLNs as has been previously shown in the context of anti-CTLA4 therapeutics[37] ($p<0.0001$; Extended Data Figure 6K). These findings support an additional putative mechanism of action of Fc engineered anti-CTLA4-NF antibodies, potentially distinct from Treg depletion, involving enhanced priming of tumor-specific CD8 and/or non-Treg CD4 Tconv cells.

Discussion

This study evaluated a novel next-generation non-fucosylated anti-CTLA4 antibody (BMS-986218) engineered to enhance ADCC in combination with ADT versus ADT alone prior to surgery in men with high-risk localized PCa. We demonstrated that anti-CTLA4-NF shows promising signs of biological activity to counteract ADT-induced Treg expansion in patients, consistent with its proposed mechanism of action, and promotes successful immune priming in PCa. Anti-CTLA4-NF treatment also demonstrated a tolerable safety profile in the pre-surgical setting and potential clinical activity with a lower-than-expected rate of recurrence.

To determine potential mechanisms underlying the immunological effects of anti-CTLA4-NF on the TME, we utilized multiple analytic methods to interrogate changes in immune phenotypes at the single-cell level on prostatectomy specimens. These studies revealed both expected and novel associations with response to therapy. We showed for the first time in patients that anti-CTLA4-NF elicits measurable TI-Treg depletion through engagement of the activating FcγR CD16a on tumor macrophages and that the depth of Treg depletion correlates with clinical outcome. Our findings thus support the mechanism established in pre-clinical models but for which limited clinical evidence currently exists[16,29]. These findings also support the hypothesis that first-generation anti-CTLA4 antibodies ipilimumab and tremelimumab fail to deplete TI-Tregs in humans due to inefficient engagement of CD16a on TAMs. A possible explanation for this phenomenon is that non-engineered anti-CTLA4 IgG1 antibodies preferentially engage the inhibitory FcγR *FCGR2B*/CD32b on myeloid cells, preventing TI-Treg-directed ADCC/P[38]. Complicating this mechanism is our observation that inhibitory *FCGR2B* and

activating *FCGR3A* receptors are highly co-expressed on tumor associated macrophages. Additional studies are warranted to understand how co-expression patterns of *FCGR3A* and *FCGR2B* on TAMs influences efficiency of Treg depletion by Fc-engineered antibodies targeting CTLA-4. An alternative mechanism supported by our data is that tumors with low baseline frequencies of *FCGR3A*/CD16a+ TAMs – or physical segregation of these macrophages from TI-Tregs – may fail to respond to anti-CTLA4-NF. A positive role for *FCGR3A*/CD16a^{+} TAMs in the context of anti-CTLA4-NF is notable, as *FCGR3A*/CD16a^{+} TAMs are generally enriched for the immunosuppressive, M2-like phenotype (e.g. TREM2^{+} and CD206^{+} TAMs in our study) that plays a negative prognostic role in many cancers[22]. However, the role of these TAMs may vary in distinct therapeutic contexts. Recent data suggest M2-like TAMs may in fact be necessary to organize antitumor immune responses[39], which together with our findings challenges the narrative that M2-like TAMs are universally antagonistic to cancer immunotherapies. In either case, pre-clinical studies suggest anti-CTLA4-mediated FcγR engagement on tumor macrophages can elicit pro-inflammatory macrophage skewing[40]. Therefore, Fc-engineered anti-CTLA4 antibodies may deliver a broadly applicable, and possibly synergistic, dual benefit of TI-Treg depletion and M2-to-M1 macrophage skewing that may be effective in overcoming the immunosuppressive microenvironment of many tumor types that do not respond to ICB.

Although anti-CTLA4-NF decreased TI-Treg frequency in PCa patients, TI-Treg depletion was not complete. Residual Tregs in tumors following treatment with anti-CTLA4-NF appear to exhibit a highly activated phenotype. While our current studies were not able to confirm whether these Tregs were functionally immunosuppressive,

these findings indicate a potential limitation of TI-Treg depleting therapies that target a single coinhibitory receptor such as CTLA4. We hypothesize that TI-Tregs undergoing blockade of CTLA4 without experiencing ADCC/P (whether through engagement of *FCGR2B* on proximal TAMs or spatial segregation from ADCC/P effectors) become activated as a result of less coinhibitory receptor activity, as has been observed in mice receiving anti-CTLA4 or in context of anti-PD1 blockade[37,41]. Notably, we found these Tregs to be enriched in other potentially targetable surface proteins, such as CCR8, CD25, CD39, and 4-1BB. Fc competent and glycoengineered antibodies targeting CCR8 are currently in clinical development[42,43]. Thus, co-delivery of glycoengineered antibodies targeting CTLA-4 and CCR8 may be additive or synergistic, given the potential capacity for anti-CCR8 to deplete TI-Tregs remaining following anti-CTLA4, and that anti-CTLA4 elicits enhanced T cell priming and myeloid activation. Recent studies also suggest CD4 Tconv in tumors depleted of TI-Tregs upregulate CCR8 and become functionally immunosuppressive[44]. These studies warrant additional basic and clinical studies of glycoengineered antibodies targeting CTLA4 and CCR8 in prostate or other cancers.

In addition to Treg depletion, we found that our glycoengineered anti-CTLA4 antibody enhanced T cell priming, potentially by increasing interactions between CTLA4+ effector T cells and FcγR+ dendritic cells. High tumor DC frequencies in our data were significantly associated with lack of disease recurrence in patients receiving ADT + anti-CTLA4-NF. In addition, only patients treated with anti-CTLA4-NF elicited the distinct $CD39^{+}41BB^{+}$ phenotype in tumor-infiltrating CD8 and CD4 T cells, mirroring established phenotypes for tumor-specific T cells ($CD39^{+}CD103^{+}$[35]) and recently primed

tumor-specific cells (41BB^{+}). Our pre-clinical studies in the murine syngeneic MycCaP model were in striking agreement with these clinical data, and prior *in vitro* work with human T cells and DCs in context of bacterial superantigen-mediated stimulation suggest FcγR engagement on APCs is required for enhanced priming activity of antibodies targeting CTLA-4, independent of Treg depletion[45]. Our pre-clinical findings that FcγR-engaging – but not FcγR-silenced – anti-CTLA-4 antibodies elicit a significant phenotypic shift in tumor DCs suggests a bi-directional effect on both T cells and DCs, reminiscent of observed inflammatory polarization of macrophages post-anti-CTLA-4 in other murine models[40]. Nevertheless, increasing evidence indicates spatial co-localization of effector CD8 and CD4 T cells with DCs in tumors (termed immune "triads," "hubs" or "networks"[46,47]) is critical for productive antitumor immune responses. Further investigation is warranted to determine whether Fc-enhanced antibodies targeting CTLA-4 or other immune checkpoints can facilitate accumulation of these specialized immune clusters in human tumors, and whether this is an essential underlying mechanism of action of these therapeutics.

One limitation of our study was the relatively small sample size making interpretation of clinical activity of ADT + anti-CTLA4-NF challenging. Although we observed a lower rate of recurrence following surgery than would be expected based on established risk nomograms, both ADT alone and ADT plus anti-CTLA4-NF demonstrated favorable outcomes. A second limitation was that our study was not designed with sufficient power to compare outcome differences between the treatment arms. In terms of profiling data; given that our CyTOF and scRNAseq was performed on freshly collected specimens, all comparisons were made between treatment groups as

opposed to matched pre- and post-treatment tissue, which was not available. However, the arms were relatively well balanced and previous data suggests comparisons between pre-treatment biopsies and surgical resection tissue may be confounded when assessing the immune TME[48]. Clinically, it is notable that development of BMS-986218 has been discontinued (NCT03110107), however, several related second-generation depleting anti-CTLA4 antibody agents (botensilimab/AGEN1181, ONC-392, ADG216) are in clinical development. Of note, recent findings from Chand *et al.* indicate botensilimab, an Fc-enhanced DLE-mutated anti-CTLA4-hIgG1 antibody, depletes TI-Tregs in an FcγR-dependent fashion across cancer types and potentially modulates DCs, closely mirroring our pre-clinical and clinical findings with BMS-986218 in PCa[12].

Unfortunately, ICB has been ineffective for the vast majority of patients with prostate cancer. However, a more nuanced appreciation of key mechanisms of immune tolerance in prostate cancer and how these evolve with disease progression and vary by site of disease is allowing for the development of novel therapeutic approaches. Our study builds on prior work demonstrating that ADT rapidly elicits a particularly robust immune response in the neoadjuvant setting but is limited by adaptive Treg resistance[11]. In murine prostate cancer models ADT combined with Treg depletion results in durable tumor control supporting the development of novel Treg depletion strategies in patients[10]. Prior studies have evaluated ipilimumab prior to surgery in prostate cancer but have demonstrated limited efficacy and significant toxicity[49] (also see NCT02020070).

Although traditional drug development has focused on heavily pre-treated advanced disease first to establish clinical efficacy before moving to earlier disease

settings, this approach has several shortcomings in the context of immunotherapy. In particular the neoadjuvant setting may be uniquely effective given the abundance of tumor antigens, presence of tumor-draining lymph nodes to allow for tumor antigen cross-presentation and T cell priming, and overall more permissive immune tumor microenvironment. Furthermore, the neoadjuvant setting opens a unique window of opportunity to rapidly assess biological mechanisms of response versus resistance that are challenging in other disease settings. In the NeoRED-P study, we establish the feasibility of such an approach using a novel agent that has not previously been tested in prostate cancer.

In conclusion, we demonstrate the safety and feasibility of anti-CTLA4-NF (BMS-986218) in combination with ADT prior to surgery in men with high-risk localized prostate cancer. Our robust immune profiling studies provide first-in-human evidence of TI-Treg depletion by glycoengineered antibodies targeting CTLA-4. In combination with pre-clinical modeling these findings support both canonical and novel mechanisms underlying activity of ADCC/P-competent anti-CTLA4. Our study also identifies immunological correlates of clinical response to ADT + anti-CTLA4-NF, supporting a potential role for immunotherapy targeting CTLA-4 in patients with prostate cancer.

Tables

Table 1. Patient Baseline Demographics and Disease Characteristics

Characteristic	ADT N=10[1]	ADT + αCTLA-4-NF N=14[1]
Age		
Median (Range)	66.0 (52.0, 72.0)	65.5 (52.0, 77.0)
Race, n (%)		
White	6 (60%)	9 (64%)
Black	2 (20%)	2 (14%)
Asian	1 (10%)	0 (0%)
Other	1 (10%)	3 (21%)
Ethnicity, n (%)		
Not Hispanic	7 (70%)	12 (86%)
Hispanic	3 (30%)	2 (14%)
PSA[2]		
Median (Range)	18.44 (2.37, 94.40)	9.08 (4.57, 364.70)
Testosterone		
Median (Range)	420.30 (153.90, 553.30)	399.50 (273.80, 783.30)
Grade group, n (%)		
3	5 (50%)	2 (14%)
4	3 (30%)	5 (36%)
5	2 (20%)	7 (50%)
T stage, n (%)		
T2	5 (50%)	4 (29%)
T3a	2 (20%)	5 (36%)
T3b	3 (30%)	5 (36%)
Nodal involvement, n (%)	2 (20%)	3 (21%)
Surgical margin involvement, n (%)	3 (30%)	3 (21%)
2-year recurrence-free probability		
Median (Range)	69.50 (8.00, 88.00)	55.00 (4.00, 82.00)
VHR, n (%)[3]	8 (80%)	12 (86%)

[1] Median (Range) for continuous variables; N (%) for categorical variables

[2] Prostate-specific antigen (PSA), ng/mL

[3] Very high-risk (VHR) group defined by National Comprehensive Cancer Network (NCCN) criteria as Gleason ≥8 or PSA >20 ng/ml or clinical T3 stage or higher

Table 2. Treatment-related adverse events

Treatment-related adverse events (TRAEs)[1]	ADT N = 10		ADT + αCTLA-4-NF N = 14	
	All grades	Grade ≥3	All grades	Grade ≥3
Any treatment-related adverse event (TRAE)	8 (80)	—	10 (71)	1 (7.1)
Gastrointestinal disorders	—	—	3 (21)	—
Colitis	—	—	1 (7.1)	—
Diarrhea	—	—	1 (7.1)	—
Elevated transaminases	—	—	1 (7.1)	—
General disorders and administration site conditions	7 (70)	—	8 (57)	—
Chills	1 (10)	—	—	—
Fatigue	—	—	4 (29)	—
Hot flashes	5 (50)	—	6 (43)	—
Injection site reaction	6 (60)	—	7 (50)	—
Investigations	—	—	—	1 (7.1)
Lipase increased	—	—	—	1 (7.1)
Musculoskeletal and connective tissue disorders	—	—	1 (7.1)	—
Bone pain	—	—	1 (7.1)	—
Nervous system disorders	—	—	1 (7.1)	—
Headache	—	—	1 (7.1)	—
Reproductive system disorders	2 (20)	—	—	—
Erectile dysfunction	2 (20)	—	—	—
Skin and subcutaneous tissue disorders	—	—	1 (7.1)	—
Pruritus	—	—	1 (7.1)	—

[1] Treatment-related adverse events (TRAEs) graded according to NCI CTCAE v5.0

Table 3. Study Outcomes

Outcome	N	ADT N=10[1]	ADT + αCTLA-4-NF N=14[1]
PSA response rate[2]	22	3 (33%)	7 (54%)
Undetectable PSA at 12 months	23	8 (80%)	10 (77%)
Time recurrence-free (months)	23		
Median (Range)		23.8 (2.2, 25.3)	22.9 (3.2, 26.6)
Overall recurrence	24	2 (20%)	4 (29%)

[1] Median (Range) for continuous variables; N (%) for categorical variables

[2] PSA reponse rate defined as >50% decrease in PSA prior to prostatectomy

Figure Legends

Figure 1: NeoRED-P trial design and clinical outcomes. (A) Schematic of NeoRED-P clinical trial design. **(B)** NeoRED-P trial consort diagram. **(C)** Kaplan-Meier curve of PSA recurrence-free survival in patients treated with neoadjuvant ADT. **(D)** Kaplan-Meier curve of PSA recurrence-free survival in patients treated with neoadjuvant ADT + anti-CTLA4-NF. Predicted median 2-year RFS in **(C)** and **(D)** were calculated from the Memorial Sloan Kettering Cancer Center Post-Radical Prostatectomy Prediction risk nomogram. **(E)**. Percent change in serum PSA from pre-treatment to time of surgery in ADT arm patients. Dotted line denotes 50% decline in PSA (PSA50). **(F)** Percent change in serum PSA from pre-treatment to time of surgery in ADT + anti-CTLA4-NF arm patients.

Figure 2: Multi-omic single cell analysis of Treg depletion by ADT + anti-CTLA4-NF. (A) Schematic of immune correlates performed. **(B)** Summary of data collection and QC passing at a per-patient level for CyTOF, scRNAseq, and immunofluorescence datasets. Patients are additionally annotated according to presence or absence of PSA recurrence within 2 years post-surgery. **(C)** Representative images from whole-slide immunofluorescence data for CD4 and FoxP3 with DAPI nuclear staining. Inset grey box shows a representative $CD4^{+}FoxP3^{+}$ cell at 2.5x magnification relative to the original image. Scale bar = 40µm. **(D)** Violin plot representing Treg density as measured by Treg cell number per mm^2 between NeoRED-P treatment groups and untreated controls in the immunofluorescence dataset. **(E)** UMAP plot of single cell RNAseq data

from all patients, clustered using the PICSES analytical pipeline. **(F)** Bubble plot of representative gene expression for each cluster identified in **(E). (G)** Supervised UMAP plot of CyTOF data from all patients, clustered using FlowSOM. **(H)** Heatmap of lineage-defining protein expression across all clusters. Data represents geometric MFI for each marker normalized to the minimum and maximum values across all clusters. **(I)** UMAP plot representing subclustering of the scRNAseq T/NK cluster shown in **(E)**. **(J)** Visualization of per-cell normalized enrichment scores for a published Treg gene set across all T/NK cells in the scRNAseq dataset. **(K)** Bubble plot of inferred protein activity for manually selected Treg-related proteins across all T/NK subclusters as calculated by VIPER. **(L)** Violin plot representing Treg frequencies as a percent of total cells between NeoRED-P treatment groups and untreated controls in the scRNAseq data. **(M)** Overlay of FlowSOM-derived Treg and CD4 Tconv clusters in the CyTOF data on bi-axial plots representing canonical Treg phenotypes. **(N)** Heatmap of all Treg-relevant phenotypic marker expression in the CyTOF panel, normalized as described in **(H).** Markers with universally high or low expression were scaled according to the minimum and maximum of all FlowSOM clusters. **(O)** Violin plot representing Treg frequencies as a percent of total cells between NeoRED-P treatment groups and untreated controls in the CyTOF data. All statistical tests in this figure utilized Student's t test.

Figure 3: Phenotypic analysis of TI-Tregs and association with clinical outcomes. **(A)** PaCMAP plot representing FlowSOM-derived Treg clusters in the CyTOF data. Data presents 17,757 total cells across 25 patients with evaluable data. Clusters were

manually annotated according to expression of relevant protein markers as visualized in **(B)** as colorimetric expression maps of selected markers overlayed on the parent PaCMAP plot, or **(C)** heatmap expression of all relevant markers across all clusters. Data represents geometric MFI for each marker normalized to the minimum and maximum values across all clusters. Markers with universally high or low expression were scaled according to the minimum and maximum of all $CD45^+$ FlowSOM clusters. **(D)** Density plots representing Treg cell location on the PaCMAP plot in **(A)** iterated by treatment group. **(E)** Stacked box plot quantifying relative frequencies of all Treg FlowSOM-derived clusters as a percent of Tregs the PaCMAP plot in **(A)** iterated by treatment group. **(F)** Bubble plot representing relative expression of phenotypic markers in Tregs from ADT + anti-CTLA4-NF group versus Tregs in the ADT only group, as calculated by $\log_2$ transformed ratio of average geometric MFI of each marker on Tregs from ADT + anti-CTLA4-NF versus ADT groups. Bubble size represents relative gMFI, while color intensity represents percent expression of indicated markers across all Tregs in the dataset. Red color indicates higher relative gMFI in Tregs from patients treated with ADT + anti-CTLA4-NF, while blue color indicates higher relative gMFI in patients treated with ADT only. **(G)** Violin plot representing frequency of Tregs at time of surgery in the scRNAseq dataset stratified by 2-year PSA recurrence status. Student's t-test was performed to evaluate statistical significance. **(H)** Kaplan-Meier curve representing time-to-PSA recurrence in ADT + anti-CTLA4-NF treated patients stratified by Treg frequency (in scRNAseq data). Log-rank test was performed to evaluate statistical significance.

Figure 4: Myeloid correlates of Treg depletion and response to anti-CTLA4-NF. (A) UMAP plot representing subclustering of myeloid cells in the scRNAseq dataset utilizing the PISCES pipeline. **(B)** Visualization of representative gene expression overlayed on the parent UMAP plot to validate cluster annotations. **(C)** Bubble plot validating expression of additional cluster defining genes. **(D)** Visualization of VIPER-inferred protein activity of select Fcγ receptors across myeloid clusters in UMAP space. **(E)** Violin plot of *FCGR3A*/CD16a inferred protein activity on a per cell level stratified by myeloid cluster. **(F)** Correlation between Treg frequency and average inferred protein activity of *FCGR3A*/CD16a across all myeloid cells on a per patient basis, stratified by treatment group. **(G)** Correlation between Treg frequency and average inferred protein activity of *FCGR3A*/CD16a across TREM2^{+} TAM cluster cells on a per patient basis, stratified by treatment group. Pearson correlations were utilized to evaluate statistical significance of correlations. **(H)** Violin plot of myeloid cluster frequencies as a percent of myeloid cells stratified by treatment group. **(I)** Violin plot of myeloid cluster frequencies as percent of myeloid cells stratified by patient 2-year PSA recurrence status. Student's t-test was utilized to test statistical significance. **(J)** Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency. Log-rank test was performed to evaluate statistical significance. **(K)** Schematic of pre-clinical validation experiment in the MycCaP model. **(L)** Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. **(M)** Kaplan-Meier curve representing survival of mice shown in **(K-L)**. Log-rank (Mantel-Cox) test was used to evaluate statistical significance. **(N)** Top: Supervised

UMAP of live CD45$^+$ cells from MycCaP tumors harvested following therapy as denoted in **(K-M)**. Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Bottom: Heatmap of lineage-defining markers across all clusters. Data represents geometric MFI for each marker normalized to the minimum and maximum values across all clusters. **(O)** Frequency of TI-Tregs and cDCs as percent of all live CD45$^+$ cells, stratified by treatment group. **(P)** PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins, representative markers shown at right. Below: Pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. **(Q)** Violin plot representing frequency of PD-L2$^+$ DCs as percent of all live CD45+ events stratified by treatment group. Student's t-test was used to assess statistical significance. All murine data shown is representative of two independent experiments of 5-10 mice per group each for survival and immune profiling studies.

Figure 5: Phenotypic modulation and induced priming of CD8 T cells by anti-CTLA4-NF. (A) UMAP plot representing subclustering of CD8 T cells in the scRNAseq data utilizing the PICSES pipeline. **(B)** Visualization of representative gene expression signatures or inferred activity of indicated proteins overlayed on the parent UMAP plot to validate cluster annotations **(C)** Violin plot of CD8 T cell cluster frequencies as a percent of CD8 T cells stratified by treatment group. **(D)** PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. **(E)** Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment

group. **(F)** Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. **(G)** Violin plot representing frequency of manually gated $CD39^{+}4\text{-}1BB^{+}$ CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. **(H)** PaCMAP plot of NeoRED-P patient tumor-infiltrating $CD4^{+}$ $FoxP3^{-}$ Tconv cells by CyTOF. Clusters were derived from FlowSOM. **(I)** Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. **(J)** Expression of CD39 and 4-1BB by geometric MFI on CD4 Tconv as represented by color mapping on PaCMAP plot. **(K)** Violin plot representing frequency of manually gated $CD39^{+}4\text{-}1BB^{+}$ CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. **(L)** PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. **(M)** Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. **(N)** Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. **(O)** Violin plot representing frequency of manually gated $CD39^{+}4\text{-}1BB^{+}$ CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. **(P)** Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor draining lymph nodes of mice shown in **(L-O)**. **(Q)** Biaxial plots representing expression of CD44 and Ki67 on $CD4^{+}FoxP3^{-}$ Tconv cells in tumor draining lymph nodes of mice shown in **(L-O)**. **(R)** Violin plots representing frequencies of $CD44^{+}Ki67^{+}$ CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Student's t-test was used to assess statistical significance. All murine data shown is representative of two

independent experiments of 5-10 mice per group each for survival and immune profiling studies.

Methods

Patients

Key eligibility criteria included histologically confirmed adenocarcinoma of the prostate (clinical stage T1c-T3b, N0, M0) with no detectable metastatic involvement of lymph nodes, bone, or visceral organs and high-risk disease as defined by central pathologic review of at least two biopsy cores with Gleason sums of ≥4+3. Patients were required to demonstrate adequate bone marrow, hepatic, and renal function. Prior exposure to radiation therapy, chemotherapy, immunotherapy, biologic therapy, or concomitant treatment with hormonal therapy and/or systemic corticosteroids (with the exception of short courses <5 days 7 days or more prior to treatment initiation) was not allowed. See full trial protocol in Supplementary Information for additional detail.

Clinical Trial Regulatory Oversight and Approval

This trial was approved and all amendments reviewed by the Columbia University Institutional Review Board (IRB) under the protocol number AAAS3560. The trial was registered with ClinicalTrials.gov on March 6, 2020, with the ClinicalTrials.gov ID NCT04301414. All patients provided informed consent prior to enrollment in the study.

Clinical Trial Design

This was a single-center, randomized, two-arm, open label pilot study conducted at Columbia University Irving Medical Center to evaluate the safety, feasibility, and immunogenicity of neoadjuvant degarelix (ADT) or BMS-986218 (anti-CTLA4-NF) plus ADT prior to radical prostatectomy in men with high-risk localized prostate cancer.24 patients were enrolled in the study. The first 4 patients were assigned to receive ADT + anti-CTLA4-NF as a safety lead-in. Thereafter, 10 patients each were randomized to the two treatment arms. In the ADT-only arm, men received 240 mg degarelix acetate subcutaneously two weeks prior to surgery. In the ADT + anti-CTLA4-NF arm, men received 20 mg BMS-986218 intravenously on day 1 and day 15, and 240 mg degarelix acetate subcutaneously on day 8, starting 3 weeks prior to prostatectomy (Figure 1A).

Clinical Trial Endpoints and Assessments

The primary objective was to characterize safety, tolerability, and feasibility of ADT with or without anti-CTLA4-NF in the neoadjuvant setting. The secondary objectives included: (i) evaluation an immune response consistent with the proposed mechanism of action of anti-CTLA4-NF, specifically the effect on intratumoral Treg density and CD8:Treg ratio, (ii) estimation of the pathologic complete response rate following neoadjuvant anti-CTLA4-NF plus ADT as compared to ADT alone, (iii) estimation of the PSA50 response rate and rate of undetectable PSA at 12 months following neoadjuvant anti-CTLA4-NF plus ADT as compared to ADT alone, and (iv) estimation of the rate of post-surgical PSA recurrence within two years of completing therapy between patients receiving ADT alone versus ADT plus anti-CTLA4-NF.

Serum PSA and testosterone levels were measured on all patients prior to therapy initiation and at time of surgery. Thereafter, serum PSA and testosterone was measured on all patients every 3 (±1) months during the first post-operative year and every 6 (±2) months during the second and third post-operative years. Adverse events were monitored during the course of therapy and until at least two years post-surgery and registered according to CTCAE version 5.0. Adverse events were deemed associated or not associated with ADT and/or anti-CTLA4-NF according to the treating physician. Peripheral blood was drawn weekly during the course of treatment and at follow-up visits after surgery. Tumor samples from prostatectomy specimens were collected at time of surgery; fresh tissue was collected and processed as described below, and archival formal-fixed paraffin-embedded (FFPE) tissues were obtained for indicated correlative studies.

Tumor Sample Collection & Processing

Following radical prostatectomy, surgical tissues were grossed and sectioned by pathologists at Columbia University Irving Medical Center. Up to 1 gram of tumor tissue was collected in Miltenyi MACS Tissue Storage Solution on wet ice, massed, washed with PBS, then diced with microdissection scissors to 1-2mm pieces in a 5mL Eppendorf tube. Tissue pieces were transferred into a Miltenyi C tube (0.5g per tube) in serum free RPMI, then enzymes H, R, and A were added according to the Miltenyi Human Tumor Dissociation Kit protocol. Tumors were digested on a gentleMACS

Octodissociator under program 37_multi_A_01. Once finished, RPMI supplemented with 5% FBS (R5 media) was added to quench digest enzymes, then suspensions were filtered (70um) into a 15mL conical tube and spun at 400xg for 5 minutes at 4° C. Pellets were RBC lysed by resuspension in Miltenyi 1x ACK buffer for 5 minutes at RT, followed by centrifugation at 300xg for 5 min at 4° C. Pellets were washed with R5, filtered, and pelleted. Cell numbers were then quantified on a Countess II automated cell counter, then samples were split for downstream analysis by CyTOF and single cell RNA sequencing.

Tumor Whole Exome Sequencing

Baseline germline mutation testing was performed at trial screening using the Invitae Common Hereditary Cancers Panel (48 genes) or the Invitae Multi-Cancer Panel (70 genes). Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens with >30-40% tumor content were sectioned at 5uM by the Herbert Irving Comprehensive Cancer Center's (HICCC) Molecular Pathology Shared Resource (MPSR). Hematoxylin and eosin (H&E) slides were reviewed and tumor area marked by a board-certified pathologist. Tissue sections were submitted for mutational profiling to Columbia University Irving Medical Center's Laboratory of Personalized Genomic Medicine, a CAP-accredited and CLIA-certified clinical genomics laboratory. Tissue was prepared for sequencing as previously described[50].

Targeted next-generation sequencing of tumor DNA and cDNA was performed using the Columbia Combined Cancer Panel (CCCP), a New York State Department of Health-certified panel, covering 467 cancer-related genes Raw sequencing data were mapped to the human reference genome (GRCh37, hg19), and analyzed for single nucleotide variants, small insertions and deletions, copy number alterations, gene rearrangements and fusions, tumor mutation burden, and microsatellite instability using validated clinical pipelines. Identified genomic alterations were reviewed and interpreted for pathogenicity and clinical significance by a board-certified molecular pathologist. See supplementary Information for genes covered in all genomic testing panels and panel-specific methodologies.

Mass Cytometry

Cell pellets were resuspended in R5 supplemented with Rh103 viability stain (1:500) in a 1.5mL protein lo-bind tube and incubated 15 min at 37° C. Cells were pelleted, washed once with R5 media, then resuspended in 49ul Cell Staining Buffer (CSB; Fluidigm) followed by addition of 1ul Fc Block (TruStain FcX; BioLegend). Samples were mixed and incubated for 5-10 minutes on ice. Separate surface and intracellular antibody cocktails were pre-mixed and stored at -80° C; during the Fc Block incubation cocktails were thawed on ice, the surface mix was spun through a PVDF centrifuge filter for 3 min at 1200rpm, then 50ul surface mix was added to the cell suspension for a final volume of 100ul. Surface staining was conducted on ice for 30 minutes, then cells were washed twice with 1mL CSB. Cells were fixed by resuspending in 500ul FoxP3 Fixation/Permeabilization buffer (eBioscience) and incubating at RT for 30 minutes. Fixative was washed out with two successive washing steps with 1mL 1X Perm Wash. For intracellular staining, cells were resuspended in 49ul 1X PW + 1ul heparin on ice. Intracellular cocktails were diluted to 50ul with 1X PW and were spun through a PVDF membrane prior to addition to the cell solution for a final staining volume of 100ul. Cell staining was conducted on ice for 30 minutes, followed by two successive washes with 1mL 1X PW. Fully stained cells were fixed in 400ul FixIR solution (2.4% PFA + 0.25 nM Ir-191/193) at room temperature for 30 minutes. Samples were washed with 600ul CSB and spun for 4 min at 600 xg, and washed again with 1mL CSB. Samples were either resuspended in CSB and held at 4° C for a maximum of 72 hours before being acquired on a CyTOF Helios at the Columbia University Human Immune Monitoring Core (HIMC), or frozen at -80° C in FBS + 10% DMSO before being thawed and acquired on a CyTOF Helios at either the Columbia University HIMC or the Mayo Clinic Immune Monitoring Core (IMC). All samples were acquired with, and data was normalized using spiked in four-element EQ Calibration Beads (Fluidigm/Standard BioTools) for longitudinal and cross-platform standardization.

Single Cell RNA Sequencing and Analysis

Cells were processed for scRNAseq using the 10X Chromium 3’ v2 Library and Gel Bead Kit (10x Genomics) according to manufacturer’s instructions at the Columbia

University HIMC and as described previously[22]. ScRNASeq data were processed with Cell Ranger software at the Columbia University Single Cell Analysis Core. Illumina base call files were converted to FASTQ files with the command “cellranger mkfastq.” Expression data were processed with “cellranger count” on the pre-built human reference set of 30,727 genes. Cell Ranger performed default filtering for quality control. The Seurat package was used for quality control filtering of cells, excluding those with fewer than 10% mitochondrial RNA content, more than 1,500 unique UMI counts, and fewer than 15,000 unique UMI counts. Pooled distribution across all samples of UMI counts, unique gene counts, and percentage of mitochondrial DNA after QC-filtering is shown in Extended Data Figure 3A.

Gene Expression Clustering and Initial Cell Type Inference | Combined and normalized gene expression matrix was visualized by UMAP projection and unsupervised clustering was performed using the Louvain algorithm applied to top50 principal components of the full data matrix, with optimal clustering resolution determined by bootstrapped silhouette score optimization, as described in prior work[22]. Broad cell types were inferred by SingleR with blueprint-ENCODE reference of sorted cell types, with each cluster consensus-labelled by majority-inferred cell type[24]. Further re-labelling of tumor cell clusters (labelled as epithelial by SingleR) was performed by InferCNV analysis, demonstrating consistent regions of chromosomal aberration above background rate seen in other cell types[26].

Regulatory Network Inference | For each gene expression cluster, a gene regulatory network was inferred on log-normalized counts by the ARACNe algorithm[51] to identify downstream transcriptional targets of regulatory proteins. ARACNe was run with 100 bootstrap iterations using 1785 transcription factors (genes annotated in gene ontology molecular function database as GO:0003700, “transcription factor activity,” or as GO:0003677, “DNA binding” and GO:0030528, “transcription regulator activity,” or as GO:0003677 and GO:0045449, “regulation of transcription”), 668 transcriptional cofactors (a manually curated list, not overlapping with the transcription factor list, built upon genes annotated as GO:0003712, “transcription cofactor activity,” or GO:0030528 or GO:0045449), 3455 signaling pathway related genes (annotated in GO biological process database as GO:0007165, “signal transduction” and in GO cellular component

database as GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 3620 surface markers (annotated as GO:0005886 or as GO:0009986, “cell surface”). ARACNe is only run on these gene sets so as to limit protein activity inference to proteins with biologically meaningful downstream regulatory targets, and we do not apply ARACNe to infer regulatory networks for proteins with no known signaling or transcriptional activity for which protein activity may be difficult to biologically interpret. Parameters were set to zero DPI (Data Processing Inequality) tolerance and MI (Mutual Information) p value threshold of 10−8, computed by permuting the original dataset as a null model.

Protein Activity Inference and Clustering | Inference of protein activity was performed from scaled integrated gene expression matrix and the set of all ARACNe-inferred gene regulatory networks using the VIPER algorithm[20,22]. Normalized Enrichment Scores of protein activity were successfully inferred on a per-cell basis for 3,437 regulatory proteins. This protein activity matrix was re-clustered in Seurat using the Louvain algorithm on top50 principal components and clustering resolution parameter optimized by silhouette score, as above, with two-dimensional data projection visualized by UMAP. Differential protein activity between clusters was computed by Wilcoxon rank-sum test with multiple testing correction. Differential abundance of each cluster per patient by treatment group was also assessed by Wilcoxon-rank-sum test, as well as differential abundance of each cluster within the combination-treatment group between patients with and without disease recurrence. Cell clusters inferred by SingleR as lymphoid lineage, myeloid lineage, or tumor cells, respectively, were each isolated for further sub-clustering analyses.

Single-cell RNA-seq T/NK Subclustering | Subsetting lymphoid cells from initial analysis resulted in a VIPER matrix of 14,208 cells, projected into their first 50 principal components using Seurat's RunPCA function, followed by using Seurat's RunUMAP function with method umap-learn. Unsupervised clustering of lymphoid cells was performed by the same silhouette score optimized Louvain approach as above. In addition to SingleR cell type labelling, we applied GSEA on cell-by-cell basis using an expression-based T-reg marker gene set previously published from Obradovic et. al. Cell 2021[22], to identify the T-reg cluster. VIPER activity of manually selected relevant

markers was also visualized for lymphoid cell subtype identification of all other clusters. Differential abundance of each cluster as percent of lymphoid cells was assessed by treatment group and by recurrence vs non-recurrence within the combination-treatment group, by Wilcox rank-sum test. The ADT-only treatment group was not stratified due to insufficient recurrences for statistical power and recurrence data were not available in the untreated group. Further testing in the combination treatment group of association between Treg abundance and time-to-recurrence was performed by Kaplan-Meier analysis, with optimal cut-point of high-Treg vs low-Treg samples determined by log-rank maximization, and p-value assessed by Cox regression.

Single-cell RNA-seq Myeloid Cell Subclustering | Isolation of myeloid cells (clusters identified by SingleR as predominantly Monocyte or Macrophage) yielded 5771 Myeloid cells, subclustered in the same manner as lymphoid cells above. RunPCA and RunUMAP from Seurat were used to compute the first 50 principal components and UMAP respectively. Upon sub-clustering, a subpopulation identified as fibroblasts (n=183) by SingleR with the BlueprintEncode reference dataset from Celldex was removed from downstream analysis. A 7-cluster unsupervised clustering solution was selected as optimal by maximization of silhouette score. Clusters were then annotated by cell type with a combination of visualizing manually selected phenotypic markers and assessing Gene Set Enrichment of differentially active proteins by cluster.

Correlation Between FCGR3A Activity and Treg Frequency | In order to assess for relationship between FCGR3A protein activity among myeloid cells and Treg frequency, we performed correlative analysis between Treg frequency as a percent of lymphoid cells for each patient against average FCGR3A protein activity for myeloid cells as a whole in the same patient, as well as for the specific subset of TREM2+ TAMs. Stratifying these analyses by treatment group shows treatment-dependent association between FCGR3A activity and Treg abundance, such that in combination-treatment alone higher myeloid FCGR3A activity was found to associate with lower Treg abundance.

Single-cell RNA-seq CD8+ T Cell Subclustering | Upon sub-clustering lymphoid cells, we further isolated the two identified clusters of CD8 T-cells (CD8-1 and CD8-2) for deeper sub-phenotyping. This yielded a VIPER protein activity matrix for 7,475 cells.

Re-clustering on the top50 principal components of this matrix yielded a four-cluster solution such that one small subset of n=187 cells appeared to be naïve CD8s or potential contamination, and were removed. This conclusion was supported by GSEA on the gene expression signatures of these cells with the Naive CD8 gene set from Zheng et al. 2021[34]. The remaining true CD8+ cells were re-scaled and re-clustered yielding a three-cluster solution. These clusters were labelled as “Central Memory”, “Effector” and “Effector/Resident Memory” by Gene Set Enrichment Analysis. "Memory vs Effector" and "Effector vs Memory" signatures were generated using a Mann-Whitney U-Test between the gene expression profiles of CD8+ Trm and CD8+ cytotoxic populations reported by Tuong et al. 2021[31]. The top genes from each of these signatures and in the signatures from Zheng et al. 2021[34] were supplied as gene sets to GSEA to compute enrichment on the gene expression profiles of our CD8+ cells. Relevant manually curated marker genes were further visualized by VIPER activity per cluster. Cluster frequencies by treatment group were then calculated to identify changes in these CD8+ subtypes in response to treatment.

Immunofluorescence

Archival FFPE prostate tumor specimens were selected by a board-certified pathologist. Immunoblank slides and representative adjacent H&E slides were sectioned at 5uM by the Herbert Irving Comprehensive Cancer Center’s Molecular Pathology Shared Research (HICCC MPSR). Tissue sections were deparaffinized using a standard series of xylene and ethanol washes and rinsed with distilled water. Antigen retrieval was performed by heating the slides in citrate buffer at pH of 6.0 for 20 minutes in a pressure cooker. Slides were incubated overnight at 4°C with primary antibodies against CD4 (1:200, Abcam) and FOXP3 (1:100, Invitrogen). Subsequently, the slides were incubated for 30 minutes at room temperature with horse anti-mouse antibody (1:200, Vector Laboratories), and then for 30 minutes with Streptavidin, Alexa Fluor™ 594 conjugate (1:1000, Invitrogen). Next, the slides were incubated for 30 minutes at room temperature with goat anti-rabbit antibody (1:200, Vector Laboratories) and then for an additional 30 minutes with Streptavidin, Alexa Fluor™ 488 conjugate (1:300, Invitrogen). Slide sections were mounted at room temperature with 25uL of VECTASHIELD

Vibrance® Antifade Mounting Medium with DAPI (Vector Laboratories) and coverslipped.

Fluorescent images were acquired by the PhenoImager™ HT Instrument (Akoya Biosciences). Onboard spectral unmixing was performed using the PhenoImager HT 2.0 software (Akoya Biosciences). The images were analyzed with QuPath version 0.5.1[52]. Regions of interest were generated referencing tumor-marked H&E slides from adjacent sections. Nuclear and cell segmentation were performed using the QuPath extension StarDist 0.4.0 with the pretrained model dsb2018_heavy_augment.pb[53]. Following cellular segmentation, object classifiers were trained on each image to quantify Tregs (CD4+/FOXP3+) per mm^2 or as a percentage of all DAPI+ cells.

Mice

Male FVB mice were purchased from Jackson Laboratory (Bar Harbor, ME). Mice were 8-10 weeks old at time of use. All animals were housed in strict accordance with NIH and American Association of Laboratory Animal Care regulations. All experiments and procedures for this study were approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC).

Animal Studies

Myc-CaP cells were provided as a kind gift from Dr. Charles Drake and were verified as free of pathogen and cell line contamination using a 19-marker mouse STR panel through IDEXX BioAnalytics (Columbia, MO). Myc-CaP cells were passaged in RPMI medium (Corning; Corning, NY) supplemented with 10% FBS (Corning; Corning, NY), 100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco; Gaithersburg, MD). For tumor implantation, Myc-CaP cells at 70-90% confluence were harvested with 0.05% trypsin (Corning; Corning, NY), washed with PBS, counted, and resuspended at $10x10^6$ cells/mL in ice cold PBS. On day 0, 8–10-week-old mice were implanted on the right flank with $1x10^6$ Myc-CaP cells. Cages were randomized to treatment groups after cages were manually normalized to reduce intergroup variability, using the final tumor volume measurement values available prior to treatment. Tumor measurements were recorded in X, Y, and Z dimensions in a non-blinded fashion (largest diameter, smallest diameter, and largest height, respectively) every 2-3 days by digital caliper and tumor

volume was calculated by multiplying X*Y*Z. On day 24 when tumors were approximately 200mm^3 on average, mice received a single subcutaneous injection in the neck scruff of 625 ug degarelix acetate (ADT; Cayman Chemical; Ann Arbor, MI) resuspended in 100 µl sterile water per mouse. Appropriate treatment groups additionally received anti-CTLA4 (D) (9D9-mIgG2a) or anti-CTLA4 (ND) (9D9-mIgG2a-LALAPG) as indicated by intraperitoneal (IP) injection at 100 µg per mouse in 100 µl sterile PBS on days 24, 27, and 30. Antibodies were purchased from BioXCell (Lebanon, NH). For flow cytometry analysis, cohorts of animals were euthanized on day 32 for tissue collection and processing. For survival analysis, mice were deemed eligible for euthanasia when tumor volume exceeded 1,000 mm^3 or tumor ulceration exceeded 5 mm in diameter.

Spectral Flow Cytometry

Tissue harvest and dissociation | Following mouse euthanasia, tumor-draining inguinal lymph nodes were dissected and placed in 48-well plates containing 150 µl R10 media on ice. Tumors were harvested, massed, and up to 50 mg tumor was diced and placed in X-Vivo 15 media (Lonza; Basel, Switzerland) in 15mL Eppendorf tubes on ice. DNase (40 µl of 20 mg/mL solution; Roche; Basel, Switzerland) and Collagenase D (125 µl of 40 mg/mL solution; Roche; Basel, Switzerland) were added to tumor samples prior to incubation on a shaker at 37° C for 30 minutes. Digest reactions were quenched by adding 5mL R10 media. Tumor digests were filtered through 70 µm filters (Miltenyi; Bergisch Gladbach, GE), remaining undigested tissue was mashed with the handle end of a 3mL syringe plunger, then filters were washed with 5mL R10 prior to centrifugation. Lymph nodes were physically disaggregated with a 1mL syringe plunger in the 48-well plate. All samples were then transferred in R10 into U-bottom 96-well plates for staining.

Staining protocol | Samples were washed with PBS. Dead cells were stained by resuspension in 100 µl PBS + Live/Dead Fixable Blue dye (1:500; Invitrogen; Waltham, MA). This and all further staining or fixation steps were performed for 30 minutes at room temperature on a plate shaker protected from light, unless specified otherwise. Samples were washed 2x with PBS, then were resuspended in FACS (PBS + 3% FBS + 1mM EDTA + 10mM HEPES) supplemented with TruStain FcX (1:50; BioLegend; San

Diego, CA) and TruStain Monocyte Blocker (1:20; BioLegend; San Diego, CA) and placed on ice. Surface antibodies were prepared at optimal dilutions (see Supplementary Table S1) in FACS supplemented with Brilliant Stain Plus buffer (BD; Franklin Lakes, NJ), then were added to samples in blocking solution. After staining, samples were washed 2x with FACS buffer and fixed in 100 µl of FoxP3 Fixation/Permeabilization Kit buffer (eBioscience; San Diego, CA). Samples were washed twice with 1X Permeabilization buffer (1X PW) then were stained in 1X PW plus intracellular antibodies. Plate(s) were sealed and intracellular staining was performed overnight at 4° C on an orbital shaker. Samples were then washed twice in FACS then resuspended in 200 µl FACS and were immediately acquired on a Cytek Aurora 5-laser (UV/V/B/YG/R) cytometer. Simultaneously stained splenocyte samples or SpectraComp beads (Slingshot Biosciences; Emeryville, CA) were utilized for single stain controls as indicated in Supplemental Table S1.

Analysis of Mass Cytometry and Flow Cytometry Data

All analysis was performed using FlowJo (BD; San Diego, CA). Live, single cell, CD45+ events from all files were identified by manual gating using conventional gating strategies for CyTOF and flow cytometry data as shown in Extended Data Fig 5-6. Samples with fewer than 1,000 live CD45+ single cell events were excluded from further analysis. All live CD45+ single cell events in the CyTOF data were concatenated for high dimensional analyses, while up to 50,000 live CD45+ single cell events from the flow cytometry dataset were downsampled and concatenated for downstream analysis. Canonical immune lineages in both datasets were defined in a semi-supervised manner utilizing FlowSOM[27]. Data were purposely overclustered to 30 FlowSOM-derived clusters based on expression of lineage-defining markers in each panel. These clusters were then manually collated based on lineage marker expression to obtain the minimal possible number of canonical immune lineages. Clusters were embedded in two-dimensional space for visualization using the supervised UMAP function in FlowJo, which performs dimensionality reduction based on selected lineage-defining marker expression with incorporation of FlowSOM-derived clusters as a weighted parameter. For discovery-based subclustering of individual lineages (e.g. CD4 Tregs), an additional round of semi-supervised FlowSOM was performed in an analogous manner as

described above; involving FlowSOM-derived overclustering based on phenotypic markers differentially expressed by cells within the lineage of interest, followed by manual collation of clusters into minimal number of phenotypically distinct subclusters. For visualization of discovery-based subclustering within lineages, we utilized PaCMAP[54] dimensionality reduction to embed data in two dimensions. Absolute cell numbers and mean geometric fluorescent intensity (gMFI) data was exported for each cluster for downstream analysis. Phenotypic marker data was scaled based on the minimum and maximum gMFI values of each given marker across all live CD45+ cells or within the lineage of interest, as indicated in the figure legends.

Statistical Analyses

Baseline patient characteristics and study outcomes were computed and visualized utilizing the gtsummary package (v 1.7.2)[55], in Rstudio (R version 4.3.1, 2023-06-16). Mutational profiles were visualized using Oviz-Bio's LandScape (v1.1.1)[56]. Stratification for Kaplain Meier analyses was performed using log-rank maximization algorithm as implemented in the survminer package. CyTOF and spectral flow cytometry statistical testing was conducted in GraphPad Prism (v10.2). All other quantitative and statistical analyses were performed using the R computational environment and packages described above. Differential gene expression was assessed at the single-cell level by the MAST single-cell statistical framework as implemented in Seurat v4[57], and differential VIPER activity was assessed by Wilcoxon rank-sum test, each with Benjamini-Hochberg multiple-testing correction. Unless otherwise noted, comparisons of cell frequencies by treatment group were performed by Student's t-test or non-parametric Wilcox rank-sum test, and survival analyses were performed by log-rank test. In all cases, statistical significance was defined as an adjusted p value less than 0.05. Details of all statistical tests used can be found in the corresponding figure legends.

Acknowledgments

We would like to acknowledge the Columbia University Human Immune Monitoring Core (HIMC) for assistance with single cell RNA sequencing and the Mayo Clinic Immune Monitoring Core for assistance with CyTOF data acquisition. We would also like to acknowledge our collaborators at Bristol Myers Squibb for their help in conducting the study. Most of all we thank the patients and their families for participating in this study.

Extended Data

Extended Data Figure 1: NeoRED-P study co-mutation plot. (A) Co-mutation plot of NeoRED-P patients and stage matched untreated control cohort.

Extended Data Figure 2: PSA responses and testosterone recovery of all trial participants. (A) Median serum PSA (dark blue line; round dots) and testosterone (light blue line; squares) concentrations over time of all patients treated with ADT only. Error bars denote interquartile range. **(B)** Median serum PSA (dark red line; round dots) and testosterone (light red line; squares) concentrations of all patients treated with ADT + anti-CTLA4-NF. Error bars denote interquartile range. **(C)** Plots of serum PSA and testosterone concentrations for individual patients treated with ADT only. **(D)** Plots of serum PSA and testosterone concentrations for individual patients treated with ADT + anti-CTLA4-NF. D = day; P or RP = radical prostatectomy; M or Mo = month.

Extended Data Figure 3: Single cell RNA sequencing QC and inferCNV results. (A) Violin plots representing quality control plots of scRNAseq data stratified by treatment group, including number of unique molecular identifiers (UMIs) per cell (left), number of unique genes detected per cell (middle), and percent mitochondrial gene content per cell (right). **(B)** Plots representing outcomes of InferCNV analysis through visualization of inferred copy number aberrations. Reference immune and stromal cell populations shown above, and clusters annotated as tumor cells shown at bottom.

Extended Data Figure 4: Comparison of single cell RNA sequencing and CyTOF datasets. (A) Representative gating strategy representing isolation of viable, single cell CD45+ cells in the CyTOF dataset. **(B)** Pearson correlation plots comparing frequency of immune lineages annotated during clustering of both CyTOF and scRNAseq datasets as a percent of total cells. **(C)** Violin plots representing frequency and distribution of all lineage frequencies as percent of total cells by scRNAseq, stratified by treatment group. **(D)** Violin plots representing frequency and distribution of all lineage frequencies as percent of total cells by CyTOF, stratified by treatment group. **(E)** Violin plot representing frequency of T/NK subclusters as a percent of all cells, stratified by post-surgical 2-year recurrence status. Student's t-test was used to evaluate statistical significance. **(F)** Kaplan-Meier curve representing time-to-PSA recurrence in ADT-treated patients stratified by Treg frequency in scRNAseq data. Log-rank test was performed to evaluate statistical significance.

Extended Data Figure 5: Additional flow cytometry data related to DC modulation by ADT + anti-CTLA4 (D) in the MycCaP model. (A) Representative gating strategy of viable, single cell CD45+ cells in the spectral flow cytometry dataset derived from **(A)** tumor and **(B)** tumor draining lymph nodes. Summary of downstream analytical workflow shown at right. **(C)** Heatmap of relevant phenotypic marker expression across all tumor-infiltrating DC clusters. Data represents median MFI for each marker normalized to the minimum and maximum values across all DC clusters. Any markers exhibiting uniform low expression were normalized to the minimum and maximum values across all immune clusters to demonstrate low expression levels across clusters.

(D) Violin plots representing relative proportions of DC clusters as a percentage of all DCs in the indicated treatment groups. Two-way ANOVA with Tukey multiple testing correction was used to assess statistical significance. **(E)** Violin plots representing the frequency of PD-L2+ DCs as a percentage of DCs (left) or as a percentage of CD45 (right) in a second independent replicate experiment. Student's t-test was used to assess statistical significance.

Extended Data Figure 6: Additional CD8 phenotyping data by scRNAseq, CyTOF, and flow cytometry. (A) UMAP plot representing subclustering of combined CD8-1 and CD8-2 clusters in the original T/NK cluster, identifying 4 phenotypically unique subclusters. **(B)** Violin plots representing expression of *Cd8a* and *Cd4*, VIPER inferred protein activity of *CCR7*, and tumor-infiltrating naïve CD8 T cell GSEA scores (derived from Zheng *et al*. 2021) on a per cell basis in the scRNAseq dataset, stratified by subcluster. **(C)** Heatmap of relevant phenotypic marker expression across all tumor-infiltrating CD8 clusters in the CyTOF. Data represents geometric MFI for each marker normalized to the minimum and maximum values across all CD8 clusters. Any markers exhibiting uniform high or low expression were normalized to the minimum and maximum values across all immune clusters to demonstrate high or low expression levels across clusters, respectively. **(D)** Violin plots representing relative proportions of CD8 clusters as a percentage of all CD8s in the indicated treatment groups. Two-way ANOVA with Tukey multiple testing correction was used to assess statistical significance. **(E)** Heatmap of relevant phenotypic marker expression across all tumor-infiltrating CD4 Tconv clusters in the CyTOF. Data represents geometric MFI for each

marker normalized to the minimum and maximum values across all CD4 Tconv clusters. Any markers exhibiting uniform high or low expression were normalized to the minimum and maximum values across all immune clusters to demonstrate high or low expression levels across clusters, respectively. **(F)** Violin plots representing relative proportions of CD4 Tconv clusters as a percentage of all CD4 Tconv cells in the indicated treatment groups. Two-way ANOVA with Tukey multiple testing correction was used to assess statistical significance. **(G)** Heatmap of relevant phenotypic marker expression across all tumor-infiltrating CD8 clusters in the mouse spectral flow cytometry data. Data represents median MFI for each marker normalized to the minimum and maximum values across all CD8 clusters. Any markers exhibiting uniform high or low expression were normalized to the minimum and maximum values across all immune clusters to demonstrate high or low expression levels across clusters, respectively. **(D)** Violin plots representing relative proportions of CD8 clusters as a percentage of all CD8s in the indicated treatment groups. Two-way ANOVA with Tukey multiple testing correction was used to assess statistical significance. **(I)** Violin plots representing the frequency of CD39+41BB+ CD8s as a percentage of tumor-infiltrating CD8s (left) or as a percentage of CD45 (right) in a second independent replicate experiment. Student's t-test was used to assess statistical significance. **(J)** Violin plots representing the frequency of $CD44^{+}Ki67^{+}$ CD8s as a percentage of tdLN CD8s (left) or $CD44^{+}Ki67^{+}$ CD4 Tconv cells as a percentage of tdLN CD4 Tconv cells (right) in a second independent replicate experiment. Student's t-test was used to assess statistical significance. **(K)** Violin plots representing the frequency of Tregs as a percentage of all tdLN $CD45^{+}$ cells stratified by treatment group. Student's t-test was used to assess statistical significance.

References

1 Venturini, N. J. & Drake, C. G. Immunotherapy for Prostate Cancer. *Cold Spring Harb Perspect Med* **9** (2019). https://doi.org:10.1101/cshperspect.a030627

2 Le, D. T. *et al.* Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. *J Clin Oncol* **38**, 11-19 (2020). https://doi.org:10.1200/jco.19.02107

3 Gratzke, C. *et al.* KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. *Future Oncol* (2023). https://doi.org:10.2217/fon-2022-0776

4 Powles, T. *et al.* Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. *Nat Med* **28**, 144-153 (2022). https://doi.org:10.1038/s41591-021-01600-6

5 Petrylak, D. P. *et al.* KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. *Future Oncol* **17**, 3291-3299 (2021). https://doi.org:10.2217/fon-2020-1133

6 Antonarakis, E. S. *et al.* Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. *J Clin Oncol* **41**, 3839-3850 (2023). https://doi.org:10.1200/jco.23.00233

7 Beer, T. M. *et al.* Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. *J Clin Oncol* **35**, 40-47 (2017). https://doi.org:10.1200/jco.2016.69.1584

8 Fizazi, K. *et al.* Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. *Eur Urol* **78**, 822-830 (2020). https://doi.org:10.1016/j.eururo.2020.07.032

9 Sharma, P. *et al.* Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. *Cancer Cell* **38**, 489-499.e483 (2020). https://doi.org:10.1016/j.ccell.2020.08.007

10 Shen, Y. C. *et al.* Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. *Prostate Cancer Prostatic Dis* **21**, 113-125 (2018). https://doi.org:10.1038/s41391-017-0013-x

11 Obradovic, A. Z. *et al.* T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. *Clin Cancer Res* **26**, 3182-3192 (2020). https://doi.org:10.1158/1078-0432.Ccr-19-3372

12 Chand, D. *et al.* Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy. *Cancer Discov* (2024). https://doi.org:10.1158/2159-8290.Cd-24-0190

13 Maeda, Y. *et al.* Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab. *Nat Commun* **12**, 7280 (2021). https://doi.org:10.1038/s41467-021-27574-0

14 Rudin, C. M. *et al.* SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. *J Clin Oncol* **42**, 324-335 (2024). https://doi.org:10.1200/jco.23.01363
15 Luke, J. J., Zha, Y., Matijevich, K. & Gajewski, T. F. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. *J Immunother Cancer* **4**, 35 (2016). https://doi.org:10.1186/s40425-016-0140-2
16 Sharma, A. *et al.* Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research* **25**, 1233-1238 (2019). https://doi.org:10.1158/1078-0432.CCR-18-0762
17 Arce Vargas, F. *et al.* Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. *Cancer Cell* **33**, 649-663.e644 (2018). https://doi.org:10.1016/j.ccell.2018.02.010
18 VanDerMeid, K. R. *et al.* Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. *Cancer Immunol Res* **6**, 1150-1160 (2018). https://doi.org:10.1158/2326-6066.Cir-18-0319
19 Nava Rodrigues, D. *et al.* Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. *J Clin Invest* **128**, 4441-4453 (2018). https://doi.org:10.1172/jci121924
20 Alvarez, M. J. *et al.* Functional characterization of somatic mutations in cancer using network-based inference of protein activity. *Nature genetics* **48**, 838-847 (2016). https://doi.org:10.1038/ng.3593
21 Vlahos, L. *et al.* Systematic, Protein Activity-based Characterization of Single Cell State. *bioRxiv*, 2021.2005.2020.445002 (2023). https://doi.org:10.1101/2021.05.20.445002
22 Obradovic, A. *et al.* Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. *Cell* **184**, 2988-3005.e2916 (2021). https://doi.org:10.1016/j.cell.2021.04.038
23 Obradovic, A. *et al.* Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators. *Cancer Cell* **41**, 933-949.e911 (2023). https://doi.org:10.1016/j.ccell.2023.04.003
24 Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019). https://doi.org:10.1038/s41590-018-0276-y
25 Patel, A. P. *et al.* Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **344**, 1396-1401 (2014). https://doi.org:10.1126/science.1254257
26 De Falco, A., Caruso, F., Su, X.-D., Iavarone, A. & Ceccarelli, M. A variational algorithm to detect the clonal copy number substructure of tumors from scRNA-seq data. *Nat Commun* **14**, 1074 (2023). https://doi.org:10.1038/s41467-023-36790-9
27 Van Gassen, S. *et al.* FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry A* **87**, 636-645 (2015). https://doi.org:10.1002/cyto.a.22625

28 Zhao, S. G. *et al.* The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. *JNCI: Journal of the National Cancer Institute* **111**, 301-310 (2018). https://doi.org:10.1093/jnci/djy141
29 Simpson, T. R. *et al.* Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J Exp Med* **210**, 1695-1710 (2013). https://doi.org:10.1084/jem.20130579
30 Selby, M. J. *et al.* Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. *Cancer Immunology Research* **1**, 32-42 (2013). https://doi.org:10.1158/2326-6066.cir-13-0013
31 Tuong, Z. K. *et al.* Resolving the immune landscape of human prostate at a single-cell level in health and cancer. *Cell Rep* **37**, 110132 (2021). https://doi.org:10.1016/j.celrep.2021.110132
32 Schlothauer, T. *et al.* Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. *Protein Eng Des Sel* **29**, 457-466 (2016). https://doi.org:10.1093/protein/gzw040
33 Maier, B. *et al.* A conserved dendritic-cell regulatory program limits antitumour immunity. *Nature* **580**, 257-262 (2020). https://doi.org:10.1038/s41586-020-2134-y
34 Zheng, L. *et al.* Pan-cancer single-cell landscape of tumor-infiltrating T cells. *Science* **374**, abe6474 (2021). https://doi.org:10.1126/science.abe6474
35 Duhen, T. *et al.* Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nat Commun* **9**, 2724 (2018). https://doi.org:10.1038/s41467-018-05072-0
36 Bartkowiak, T. & Curran, M. A. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. *Front Oncol* **5**, 117 (2015). https://doi.org:10.3389/fonc.2015.00117
37 Marangoni, F. *et al.* Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. *Cell* **184**, 3998-4015.e3919 (2021). https://doi.org:https://doi.org/10.1016/j.cell.2021.05.027
38 Knorr, D. A. *et al.* FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. *Cancer Immunology Research* **12**, 322-333 (2024). https://doi.org:10.1158/2326-6066.Cir-23-0389
39 Ray, A. *et al.* Critical role of CD206+ macrophages in promoting a cDC1-NK-CD8 T cell anti-tumor immune axis. *bioRxiv*, 2023.2010.2031.560822 (2024). https://doi.org:10.1101/2023.10.31.560822
40 Yofe, I. *et al.* Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling. *Nat Cancer* **3**, 1336-1350 (2022). https://doi.org:10.1038/s43018-022-00447-1
41 Tan, C. L. *et al.* PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. *Journal of Experimental Medicine* **218** (2020). https://doi.org:10.1084/jem.20182232
42 Van Damme, H. *et al.* Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1

therapy. *Journal for immunotherapy of cancer* **9**, e001749 (2021). https://doi.org:10.1136/jitc-2020-001749

43 Whiteside, S. K. *et al.* CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. *Immunology* **163**, 512-520 (2021). https://doi.org:10.1111/imm.13337

44 Whiteside, S. K. *et al.* Acquisition of suppressive function by conventional T cells limits antitumor immunity upon T_{reg} depletion. *Science Immunology* **8**, eabo5558 (2023). https://doi.org:doi:10.1126/sciimmunol.abo5558

45 Waight, J. D. *et al.* Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. *Cancer Cell* **33**, 1033-1047.e1035 (2018). https://doi.org:10.1016/j.ccell.2018.05.005

46 Espinosa-Carrasco, G. *et al.* Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. *Cancer Cell* **42**, 1202-1216.e1208 (2024). https://doi.org:10.1016/j.ccell.2024.05.025

47 Magen, A. *et al.* Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. *Nat Med* **29**, 1389-1399 (2023). https://doi.org:10.1038/s41591-023-02345-0

48 Kemp Bohan, P. M. *et al.* Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement. *Cancer Immunol Immunother* **70**, 1465-1474 (2021). https://doi.org:10.1007/s00262-020-02784-5

49 Gao, J. *et al.* VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. *Nat Med* **23**, 551-555 (2017). https://doi.org:10.1038/nm.4308

50 Sireci, A. N. *et al.* Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center: Identification of Targetable Variants and Experience with Reimbursement. *J Mol Diagn* **19**, 277-287 (2017). https://doi.org:10.1016/j.jmoldx.2016.10.008

51 Margolin, A. A. *et al.* ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context. *BMC Bioinformatics* **7**, S7 (2006). https://doi.org:10.1186/1471-2105-7-S1-S7

52 Bankhead, P. *et al.* QuPath: Open source software for digital pathology image analysis. *Sci Rep* **7**, 16878 (2017). https://doi.org:10.1038/s41598-017-17204-5

53 Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. 265-273 (Springer International Publishing).

54 Huang, H., Wang, Y., Rudin, C. & Browne, E. P. Towards a comprehensive evaluation of dimension reduction methods for transcriptomic data visualization. *Communications Biology* **5**, 719 (2022). https://doi.org:10.1038/s42003-022-03628-x

55 Sjoberg, D. D., Whiting, K. A., Curry, M., Lavery, J. A. & Larmarange, J. Reproducible Summary Tables with the gtsummary Package. *R J.* **13**, 570 (2021).

56 Jia, W., Li, H., Li, S., Chen, L. & Li, S. C. Oviz-Bio: a web-based platform for interactive cancer genomics data visualization. *Nucleic Acids Res* **48**, W415-w426 (2020). https://doi.org:10.1093/nar/gkaa371

57 Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biology* **16**, 278 (2015). https://doi.org:10.1186/s13059-015-0844-5

Figure 1

A

NeoRED-P Key Eligibility Criteria

Diagnosis: Intermediate to high-risk localized PCa

- Histologically confirmed adenocarcinoma
- Gleason ≥4+3
- Clinical stage T1c - T3bN0M0
- No prior therapies

n = 24 patients

ADT = Degarelix 240mg subcutaneous

αCTLA4-NF = BMS-986218 20mg IV



Clinical Endpoints

Primary Endpoint:

Safety, tolerability, and feasibility

Secondary Endpoints:

Pathologic complete response rate

Time-to-PSA recurrence

PSA response rate at 12 months

PSA50 response rate at surgery

Biological Endpoints

Treg quantity and density

CD8 T cell quantity & phenotype

B



C



D



E



F



Figure 2


A
n=12
Untreated
n=10
ADT
n=14
ADT+ αCTLA4-NF
radical prostatectomy
Mass Cytometry (CyTOF)
34 markers; Treg focus
scRNAseq (10x 3' v3.1)
PISCES analysis pipeline
Spatial immune profiling
Multiplex IF
B
Untreated
ADT
ADT + αCTLA4-NF
CyTOF
scRNAseq
FoxP3 IF
2-Yr Recurrence
C
Untreated
ADT
ADT + anti-CTLA4-NF
DAPI
CD4
FoxP3
Merged
40μm
D
Immunofluorescence: Treg Density
# of Tregs / mm2
p=0.001
p=0.06
Untreated
ADT
ADT + αCTLA4-NF
E
scRNAseq: All Cells
Tum.3
Tum.1
T/NK
Plasma Cells
Tum.2
Tum.4
Mac/DCs
Fibroblast
Club
B
MEP
Monocyte
Endothelial
Neutrophil
UMAP 1
UMAP 2
F
T/NK Cells
B Cells
Plasma Cells
Monocytes
Mac/DCs
Neutrophils
MEP
Fibroblast
Club/Glandular
Endothelial
Tumor 1
Tumor 2
Tumor 3
Tumor 4
CD3E
CD79B
PIM2
CD14
APOE
FPR1
ARMH1
COL1A1
ATAD3C
CLDN5
FOLH1
AR
DDR1
Percent Expressed
Average Expression
G
CyTOF: Live CD45+
CD8
CD4 Tconv
pDCs
Other T
CD4 Treg
Gran.
NK
Mac/ DCs
Mono- cytes
Undef
Neutrophils
sUMAP 1
sUMAP 2
H
CD3
CD8
CD4
FoxP3
CD25
CD127
CD56
CD16
CD11b
CD33
HLA-DR
CD66b
CD14
CD163
CD123
CD141
CD8
CD4 Tconv
CD4 Tregs
Other T
NK
Neutrophils
Granulocytes
Monocytes
Mac/DCs
pDC
Undef
Normalized gMFI
I
scRNAseq: T/NK Subclustering
CD4 Tconv
CD8 1
NK
CD4 Tregs
CD8 2
UMAP 1
UMAP 2
J
Treg Gene Expression Signature
Obradovic et al. Cell 2021
Treg GSEA Score
K
Selected Treg Proteins
VIPER Inferred Protein Activity
CD4 Tconv
CD8 1
CD8 2
NK
CD4 Tregs
CD8A
FOXP3
IL2RA
IL7R
CTLA4
ICOS
IL10
GZMB
IFNG
% Active
Average Activity
L
scRNAseq: Treg Frequency
% of Total
p=0.12
p=0.06
Untr.
ADT
ADT+ αCTLA4-NF
M
CyTOF: CD4 Treg vs Tconv Conventional Phenotyping
Tregs
Tconv
FoxP3 - 162-Dy
CD25 - 169Tm
CD127 - 176Yb
N
CyTOF: Comprehensive T Cell Cluster Phenotyping
CD3
CD8
CD4
FoxP3
CD45RA
CD45RO
CD27
CD25
CD127
Helios
CCR8
CTLA-4
PD-1
Tim-3
TIGIT
OX-40
4-1BB
CD39
CCR4
GzmB
Ki67
CD8
CD4 Tconv
CD4 Tregs
Other T
Normalized gMFI
O
CyTOF: Treg Frequency
% of Total Live Cells
p=0.12
p=0.07
Untr.
ADT
ADT+ αCTLA4-NF

Figure 3


A
Tr.1
Tr.2
Tr.3
Tr.4
Tr.5
Tr.6
Tr.7
Tr.8
Tr.9
PaCMAP2
PaCMAP1
CyTOF
TI-Treg Phenotyping
Tr.1 - Memory-like
Tr.2 - Proliferating
Tr.3 - Cytotoxic
Tr.4 - Peripherally Induced
Tr.5 - CD39-
Tr.6 - CCR8-
Tr.7 - Resting
Tr.8 - HLA-DR+ Activated
Tr.9 - 4-1BB+ Activated
B
Helios
Ki67
GzmB
CD39
CCR8
CTLA-4
HLA-DR
4-1BB
Max
gMFI
Min
C
Tr.1 Tr.2 Tr.3 Tr.4 Tr.5 Tr.6 Tr.7 Tr.8 Tr.9
CD3
CD4
FoxP3
CD45RA
CD45RO
CD27
CD25
CD127
Helios
HLA-DR
CCR8
CD39
4-1BB
CTLA-4
PD-1
Tim-3
TIGIT
GITR
OX-40
CCR4
GzmB
Ki67
Normalized gMFI
0 0.2 0.4 0.6 0.8 1.0
D
Untreated
ADT
ADT + anti-CTLA4-NF
E
TI-Treg Composition
% of Tregs
100
80
60
40
20
0
Tr.1
Tr.2
Tr.3
Tr.4
Tr.5
Tr.6
Tr.7
Tr.8
Tr.9
ADT: - + +
anti-CTLA4-NF: - - +
F
CyTOF: TI-Treg Relative Marker Expression
ADT + anti-CTLA4-NF vs ADT
Relative gMFI (Log2FC)
1.5
1.0
0.5
0
-0.5
-1.0
4-1BB
GITR
CD39
CCR8
CD25
CTLA-4
Helios
CD27
TIGIT
HLA-DR
Up in ADT + anti-CTLA4-NF Tregs
Up in ADT Tregs
% of Cells Expressing
100
80
60
40
20
0
Log2FC MFI
-0.01 0.01
-0.12 0.12
-0.99 0.99
G
scRNAseq: Tregs
ADT + anti-CTLA4-NF only
p=0.03
% of Total
5
4
3
2
1
0
Recurrence: No Yes
H
scRNAseq Tregs: Time-to-Recurrence
ADT + anti-CTLA4-NF only
% Recurrence Free
100
75
50
25
0
p=0.0008
Treg-Low
Treg-High
Number at risk:
8 7 7 7 7 3
3 3 1 0 0 0
0 5 10 15 20 25
Time (Months)

Figure 4


A
scRNAseq: Myeloid Phenotyping
Cycling
TREM2+ TAMs
DCs
Inflammatory Monocytes
MT+ Macrophages
CD206+ TAMs
Classical Monocytes
UMAP 2
UMAP 1
B
S100A8
EREG
MT1H
APOE
FCER1A
EEF1B2
Min
Max
Scaled gene expression
C
Classical Monocytes
Inflammatory Monocytes
MT+ Macrophages
TREM2+ TAMs
CD206+ TAMs
DCs
Circulating Myeloid
S100A8
S100A9
EREG
CD300E
MT1H
MT1G
APOE
TREM2
MRC1
SELENOP
FCER1A
CD1C
RPS4X
EEF1B2
Fraction of cells in group (%)
20 60 100
Mean Expression
-1 0 1
D
FCGR1A
FCGR2A
FCGR2B
FCGR3A
Min
Max
Scaled VIPER protein activity
E
FCGR3A / CD16A
Classical Monocytes
Inflammatory Monocytes
MT+ Macrophages
TREM2+ TAMs
CD206+ TAMs
DCs
Circulating Myeloid
VIPER Inferred Protein Activity
F
FCGR3A / CD16A All Myeloid Cells
FCGR3A Inferred Protein Activity
ADT
ρ = 0.5
p = 0.223
ADT +
aCTLA4-NF
ρ = -0.44
p = 0.033
Treg Frequency (%)
G
FCGR3A / CD16A TREM2+ TAMs
ADT
ρ = 0.01
p = 0.767
ADT +
aCTLA4-NF
ρ = -0.46
p = 0.019
Treg Frequency (%)
H
Myeloid Clusters: Frequencies by Treatment Group
Untreated
ADT
ADT + anti-CTLA4-NF
% of Myeloid
Cla. Mono
Infl. Mono
MT+ Macs
TREM2+ TAMs
CD206+ TAMs
DCs
Cycling
I
Myeloid Clusters: ADT + anti-CTLA4-NF patients only
Recurrence?
No
Yes
p=0.06
% of Myeloid
Cla. Mono
Infl. Mono
MT+ Macs
TREM2+ TAMs
CD206+ TAMs
DCs
Cycling
J
scRNAseq DCs: Time-to-Recurrence
ADT + anti-CTLA4-NF Only
% Recurrence Free
DC-High
DC-Low
p=0.043
Number at risk:
7 7 7 6 6 2
5 4 2 2 2 1
Months
K
0
Implant SubQ MycCaP
1x10^6; 8-10 wk FVB males
24
ADT (Degarelix acetate)
+/- anti-CTLA4 (ND) or (D)
27
anti-CTLA4 (ND) or (D)
30
anti-CTLA4 (ND) or (D)
32
45c flow on tumors, tdLNs
Follow remaining mice for survival
L
MycCaP Tumor Growth Post-ADT
% Change from Baseline
Days Post ADT
M
Survival
ADT
ADT +
CTLA-4 (ND)
ADT +
CTLA-4 (D)
***
Percent Survival
Days Post ADT
N
Eosinophil
Macrophage
Neutrophil
cDC
pDC
B
NK
CD8
Monocyte
CD4 Treg
CD4 Tconv
sUMAP 2
sUMAP 1
O
Tl-Tregs
**
% of Live CD45
cDCs
***
% of Live CD45
ADT + + +
anti-CTLA4 (ND) - + -
anti-CTLA4 (D) - - +
P
45c Flow: cDCs
CD40+
DC3
CD80+
cDC1
iNOS+
DC3
cDC2
cDC1
PDL2+
DC3
PaCMAP2
PaCMAP1
CD103
CD11b
PD-L2
Max
Min
ADT
ADT +
αCTLA4 (ND)
ADT +
αCTLA4 (D)
Q
PD-L2+ DCs
***
% of Live CD45
ADT + + +
anti-CTLA4 (ND) - + -
anti-CTLA4 (D) - - +
CD3
CD8
CD4
FoxP3
TCRgd
NKp46
CD19
B220
CD11b
CD11c
IA-IE
Siglec-F
F4-80
CD64
Ly6G
Ly6C
CD8
CD4 Tconv
CD4 Tregs
CD4/CD8
TCRgd
NKT
CD3 Undef
NK
B
pDC
cDCs
Monocytes
Macrophages
Eosinophils
Neutrophils
Myeloid Undef
Undef
Normalized MFI
0 0.2 0.4 0.6 0.8 1.0

Figure 5


A
scRNAseq: CD8 Phenotyping
Effector Memory
Central Memory
Effector/Resident Memory
UMAP 2
UMAP 1
B
IL7R+ Memory
Zheng et al. 2021
Memory vs Effector
Tuong et al. 2021
CCR7
CD103
GZMK+ Early Tem
Zheng et al. 2021
Effector vs Memory
Tuong et al. 2021
GZMB
TOX2
Min
Max
Scaled GSEA NES
VIPER protein activity
C
CD8: Cluster Freq by Treatment Group
Untreated
ADT
ADT + anti-CTLA4-NF
% of CD8 T Cells
Central Memory
Effector Memory
Terminal Effector
D
Human CyTOF: CD8
Tc.1
Tc.2
Tc.3
Tc.4
Tc.5
Tc.6
Tc.7
Tc.8
PaCMAP2
PaCMAP1
E
Untreated
ADT
ADT + anti-CTLA4-NF
F
CD39
4-1BB
gMFI
Min
Max
G
CD39+41BB+ CD8
p=0.1006
% of CD8
MSIhi
Untr.
ADT
ADT+ αCTLA4-NF
H
Human CyTOF: CD4 Tconv
Tn.1
Tn.2
Tn.3
Tn.4
Tn.5
Tn.6
Tn.7
Tn.8
PaCMAP2
PaCMAP1
I
Untreated
ADT
ADT + anti-CTLA4-NF
J
CD39
4-1BB
gMFI
Min
Max
K
CD39+41BB+ CD4 Tconv
p=0.0885
% of CD4 Tconv
MSIhi
Untr.
ADT
ADT+ αCTLA4-NF
L
Mouse Flow: Tumor CD8
Tc.1
Tc.2
Tc.3
Tc.4
Tc.5
Tc.6
Tc.7
Tc.8
Tc.9
Tc.10
PaCMAP2
PaCMAP1
M
ADT
ADT + αCTLA4 (ND)
ADT + αCTLA4 (D)
N
CD39
4-1BB
gMFI
Min
Max
O
CD39+41BB+ CD8
% of Live CD45
**
ADT
anti-CTLA4 (ND)
anti-CTLA4 (D)
P
Mouse Flow: tdLN CD8
ADT
ADT + αCTLA4 (ND)
ADT + αCTLA4 (D)
Ki67 - Pacific Blue
CD44 - PerCP
Q
Mouse Flow: tdLN CD4 Tconv
ADT
ADT + αCTLA4 (ND)
ADT + αCTLA4 (D)
Ki67 - Pacific Blue
CD44 - PerCP
R
CD8
CD4 Tconv
% CD44+Ki67+
**
****
ADT
anti-CTLA-4 (ND)
anti-CTLA-4 (D)

Extended Data Figure 1



Extended Data Figure 2



Extended Data Figure 3

A



B



Extended Data Figure 4

A



B



C



E



D



F



Extended Data Figure 5

A



B



C



D



E



Extended Data Figure 6